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Abstract 
 
 
Abstract 
 
Systemic sclerosis (SSc) is a complex autoimmune disease with an incompletely understood 
pathogenesis that involves vascular damage, autoimmune-mediated inflammation, and fibrosis. 
These latter processes are heavily regulated by transforming growth factor-beta1 (TGF-β1), as it 
induces activation of fibroblasts. We hypothesized (1) that distinct NADPH oxidase (Nox) 
isoforms, especially Nox4, may regulate TGF-β1-mediated activation of human dermal 
fibroblasts (HDFs), (2) that Nox4 expression is present in SSc fibroblasts, and (3) that 
suppressing Nox activity in general, or Nox4 specifically, attenuates experimentally induced skin 
fibrosis. To test these hypotheses, we first performed a detailed expression analysis of all Nox 
isoforms and adaptor proteins at the RNA and protein levels, and we found that Nox4 is the 
major Nox isoform expressed by HDFs. Stimulation of normal HDFs with TGF-β1 resulted in a 
time- and dose-dependent induction of Nox4 at mRNA and protein levels. This effect was 
mechanistically dependent on Smad signalling and was also associated with increased NADPH 
activity. Immunofluorescence analysis using laser confocal microscopy studies further revealed 
that Nox4 localizes to the endoplasmic reticulum as demonstrated by double staining with 
protein disulfide isomerase. Nox4 expression was maintained in SSc fibroblasts. Our final set of 
experiments investigated the effects of inhibiting Nox/Nox4 activity in vitro and in vivo. 
Interestingly, pharmacologically inhibiting Nox enzyme activity in vitro by DPI, a Nox inhibitor, 
not only suppressed TGF-β1-mediated expression of collagen type I, but it also suppressed the 
induction of both α-smooth muscle actin and fibronectin 1, two established myofibroblasts 
markers. We confirmed this finding in other in vitro models. Finally, we also explored Nox 
inhibition in vivo using the bleomycin mouse model of SSc. We found that pharmacologically 
inhibiting Nox activity using DPI or treating mice with Nox4 siRNA lead to significantly 
reduced collagen content, skin fibrosis and expression of myofibroblasts markers. Overall, these 
findings show that Nox4 is a key intracellular mediator of fibroblast activation. Moreover, 
targeting Nox4 may be a novel therapeutic strategy for treating fibrotic skin diseases such as 
SSc. 
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Introduction 
 
1.  Introduction 
1.1.  Systemic sclerosis   
1.1.1.  Definition and epidemiology   
Systemic sclerosis (SSc) is an autoimmune disease characterized by immune dysregulation, 
microvascular damage inflammation, extensive fibrosis of the skin and internal organs. SSc is 
associated with mortality and is challenging to treat due to the lack of effective antifibrotic 
therapies. There is a great variability and heterogeneity between patients with SSc 
(Bhattacharyya, Wei et al. 2012, Stern and Denton 2015). According to the location of skin 
fibrosis, SSc is classified into two major clinical subtypes: limited cutaneous systemic 
sclerosis (lcSSc) and diffuse cutaneous systemic sclerosis (dcSSc). In lcSSc, fingers, distal 
extremities, hand and face are involved, whereas in dcSSc, skin fibrosis extends to proximal 
limbs and trunk. Moreover renal, cardiac and pulmonary failure may be occur more often 
(Maitre, Hours et al. 2004). 
The etiology of systemic sclerosis is not completely understood. Beside genetic 
predispositions environmental triggers such as pollution, exposure to silica or organic 
solvents, infection with cytomegalovirus have been reported to be involved in the 
pathogenesis of SSc (Hunzelmann and Brinckmann 2010, Viswanath, Phiske et al. 2013). 
The development of SSc is sex dependent as women are five times more prone to develop the 
disease than men. The incidence of SSc estimates 14-21 per million per year in both America 
and southern Europe and 100 per million in northern Europe and Great Britain, respectively 
(Mayes, Lacey et al. 2003). 
1.1.2.  The pathogenesis of systemic sclerosis 
The pathogenesis of SSc is complex and remains incompletely understood. It involves 
a complex interplay between immune system, vasculature and connective tissue system 
resulting in excessive production of extracellular matrix (ECM) and progressive fibrosis that 
is considered to be a hallmark of SSc (Figure 1). This interplay is likely the driving 
mechanism and initiates the disease development. The primary event is vascular injury that 
involves the endothelium and is initiated by viral infection, autoantibodies, toxins, or 
oxidative stress (Katsumoto, Whitfield et al. 2011). Endothelial damage then stimulates the 
release of chemokines, the generation of reactive oxygen species (ROS), the production of 
platelets-derived growth factors which causes a loss in the integrity of the endothelial lining 
and promotes recruitment and proliferation of immune cells. Under normal condition, 
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immune cells act in a coordinate manner and participate in the healing process and tissue 
repair. But under disease conditions, cells suffer from repeated injury leading to accumulation 
of macrophages, recruitment of lymphocytes and activation of T  cells at the site of injury. 
Consequently, endothelial-derived chemokines and growth factors recruit and activate both 
mesechymal progenitor cells and resident fibroblasts. In addition, profibrotic cytokines 
produced by activated T cells promote the activation of fibroblasts and their differentiation 
into persistent myofibroblasts. Pathological myofibroblasts finally produce excessive 
amounts of collagen and other ECM proteins which eventually lead to tissue contraction, 
permanent scaring and tissue fibrosis (Varga and Abraham 2007). 
 
 
Figure 1. Cellular and molecular pathways underlying fibrosis in systemic sclerosis. 
(Bhattacharyya, Wei et al. 2012). 
1.1.3.  Skin fibrosis in SSc 
Fibrosis is a distinct pathologic hallmark of SSc and is characterized by the extensive 
accumulation of fibrous matrix consisting of collagen, elastin and fibronectin. The 
accumulation leads to the disruption of the normal tissue architecture. Collagen type I is the 
most abundant protein, constituting about 85 % of skin collagens, and is composed of glycine 
and proline rich two-α1(I) and one-α2(I) chains (van der Rest and Garrone 1991). Pro 
COL1A1 and COL1A2 polypeptide chains are synthesized by fibroblasts and osteoblasts. 
2 | 
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1.1.4.  Players of skin fibrosis in SSc  
1.1.4.1.  Fibroblast and myofibroblasts 
The main effector cells in fibrosis are fibroblasts and their contractile counterpart, the 
myofibroblasts. Actually, the number of fibroblast/myofibroblast foci are considered to be a 
major prognostic factor in SSc patients (Jinnin 2010). The origins of activated fibroblasts 
within the fibrotic process are diverse (Figure 2). Firstly, fibroblasts are cells of 
mesenchymal origin which orchestrate the production of a wide variety of ECM proteins, and 
cytokines as well as growth factors such as platelets-derived growth factor (PDGF), 
transforming growth factor β1 (TGF-β1), connective tissue growth factor (CTGF), and 
interferon‐β (IFN‐β) (Denton, Black et al. 2006, Rajkumar, Shiwen et al. 2006, Kisseleva and 
Brenner 2008). Activation is associated with the appearance of α‐smooth muscle actin (α-
SMA) and altered ECM secretion. In response to injury, resident fibroblasts can be activated 
and then migrate into the injured area, where they proliferate and differentiate into 
myofibroblasts in response to profibrotic cytokines produced by the infiltrating inflammatory 
cells (Rajkumar, Shiwen et al. 2006). Kuwahara et al showed that perivascular accumulation 
of macrophages preceded both TGF-β1 expression and fibroblast proliferation (Kuwahara, 
Kai et al. 2004). Activated myofibroblasts themselves express TGF-β1 and other profibrotic 
substances which self-induce the ongoing fibrotic process (Desmouliere, Geinoz et al. 1993).  
There is growing evidence that myofibroblasts also originate from other cell types 
such as epithelial cells which transdifferentiate by a process known as epithelial 
mesenchymal transition (EMT) and most recently, endothelial cells that transdifferentiate by 
a process known as endothelial‐mesenchymal transition (EndoMT). These processes have 
been shown to be involved in renal fibrosis, pulmonary fibrosis and liver fibrosis (Wells 
2010, Chapman 2011, Fragiadaki and Mason 2011). Additionally, fibrocytes are a distinct 
population of leukocytes with characteristics of fibroblasts (Bellini and Mattoli 2007, Mathai, 
Gulati et al. 2010). These cells are recruited to sites of tissue injury by chemotaxis and play 
an important role in tissue repair by the production of matrix proteins. Excessive matrix 
protein generation may also cause pathological fibrogenesis. Microvascular pericytes have 
also been suggested to contribute to the development of fibrosis (Rajkumar, Sundberg et al. 
1999). The balance between matrix formation and degradation is disrupted in fibrotic 
diseases, usually due to the increased production and the decreased degradation of 
extracellular matrix proteins (Razzaque and Taguchi 2003). Altered number and function of 
myofibroblasts are implicated in diseases associated with increased ECM deposition (Tamby, 
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leads to the induction of fibroblast proliferation and differentiation into myofibroblasts, the 
deposition of ECM proteins as well as the induction of several pro-fibrotic genes including 
TGF-β1 and CTGF which results in excessive tissue remodeling and fibrogenesis (Bickers 
and Athar 2006, Rinnerthaler, Bischof et al. 2015).  
In 1993, Dr. Murrell hypothesized that the pathogenesis of SSc is linked to oxidative 
stress (Murrell 1993). Recently, several studies have shown permanent overproduction of 
ROS by various cells in SSc, suggesting the involvement of oxidative stress in SSc 
pathogenesis (Servettaz, Guilpain et al. 2007). Another study showed that sera from SSc 
patients with pulmonary hypertension lead to oxidative stress-induced activation of collagen 
synthesis in human pulmonary smooth muscle cells (Chaisson and Hassoun 2013). Moreover, 
oxidative stress is also involved in several pathogenic states including fibrotic pulmonary 
disorders such as idiopathic pulmonary fibrosis, liver fibrosis, cardiovascular diseases and 
chronic kidney disease. Different plasma markers of oxidative stress, i. e. protein carbonyls, 
nitrosothiols, malondialdehyde, and 8-isoprostane are found to be elevated in patients with 
SSc (Tsou, Balogh et al. 2014). Additionally, several studies have reported the contribution 
of oxidative stress in the progression of fibrosis in mice (Gabrielli, Svegliati et al. 2012). 
1.1.4.3.  The TGF-β1 signaling and its role in fibrosis 
TGF-β1 is a multifunctional cytokine and member of the TGF-β superfamily. It is 
recognized as a master regulator not only of physiological wound healing and tissue repair, 
but also of pathological fibrosis as seen in SSc (Leask and Abraham 2004). It is a 25 kDa 
polypeptide which is involved in various biological processes such as immune modulation, 
tumor suppression and promotion, tissue regeneration, wound healing, homeostasis, 
proliferation and differentiation of cells, apoptosis, adhesion, migration, inflammation and 
response to injury (O'Sullivan and Levin 2003, Hneino, Francois et al. 2012, Massague 
2012). Its mRNA and protein expression is up regulated during the pathogenesis of various 
diseases including kidney fibrosis, cardiac fibrosis, liver cirrhosis and pulmonary fibrosis as 
well as cancers. Furthermore, it secreted by various cell types including fibroblasts, T cells, 
monocytes and macrophages, platelets and many cell types also possess surface receptors 
specific for TGF-β1. Three mammalian TGF-β isoforms (TGF-β1‐3) have been identified 
(Rotzer, Roth et al. 2001). TGF-β1 is the most abundantly expressed isoform whereas TGF-β2 
was first described in human glioblastoma cells and is also expressed by neurons and 
astroglial cells in embryonic nervous system (Rotzer, Roth et al. 2001).  
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The SMAD pathway is the canonical signaling pathway that is activated directly 
by  TGF-β1 cytokines and plays an important role in regulation of collagen synthesis. 
However recent studies have also suggested the potential relevance of non-Smad pathways 
(Akhmetshina, Palumbo et al. 2012). Briefly, the Smad family consists of five receptor‐
activated Smads (Smad1-5 and 8), one common mediator Smad (Smad4) and two inhibitory 
Smads (Smad6 and 7) (ten Dijke and Arthur 2007). Once TGF-β1 bind to its heterodimer 
receptor, the TGFβ type 1 receptor (TGFβ-R1) is activated resulting in the phosphorylation of 
the Smad proteins (Smad2/3). That phosphorylation is the critical step in the initiation of the 
TGF-β1 signals. Upon phosphorylation, Smad2 and 3 form complexes with the Co‐Smad, 
Smad4, followed by the translocation to the nucleus where they could act as transcription 
factors or rather activate the transcription of specific target genes. Smad6 and Smad7 
antagonize TGF-β1 signaling by both hindering Smad2/3 phosphorylation and nuclear 
translocation of R‐Smad/Smad4 (Moustakas and Heldin 2009, Ikushima and Miyazono 2010) 
(Figure 3). 
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been reported to reduce antioxidant system such as glutathione level which plays a 
cytoprotective role in oxidative damage (Liu and Gaston Pravia 2010). TGF-β1-deficient mice 
develop numerous autoimmune disorders and are more susceptible to cancer (Hahm, Im et al. 
2000). Blockade of autocrine TGF-β1 signaling with antibodies was unable to normalize 
Smad subcellular distribution, suggesting that elevated nuclear Smad import was due to 
alterations downstream of the TGF receptors (Mori, Chen et al. 2003). There are some 
experimental anti-fibrotic drugs such as Pirfenidone that attempt to target the activation and 
proliferation of fibroblasts. These drugs were recently approved for the treatment of 
idiopathic pulmonary fibrosis in Europe and Japan (van Laar and Varga 2015). The anti-
cancer drug paclitaxel attenuated Smad activation in SSc tissue grafts in a transplantation 
model in vivo. Strategies such as antisense oligonucleotides and antibodies targeting TGF-β1 
were effectively applied in various animal models. For example, Giri and colleagues showed 
that administration of TGF-β1 antibodies could reduce bleomycin‐induced lung fibrosis in 
mice (Giri, Hyde et al. 1993). Topical application of a peptide inhibitor of TGF-β1 has been 
shown to ameliorate skin fibrosis in bleomycin-induced SSc (Dotor and Pablos 2008). In 
contrast, targeted inhibition with anti-TGF-β1 antibodies has not been shown to be successful 
in diffuse SSc. Unfortunately, a randomized clinical trial of human recombinant TGF-β1 
performed by Denton (Denton, Merkel et al. 2007) failed to improve the symptoms in SSc 
patients. However, owing to its pleiotropic effects on a wide range of cell types, it is still 
crucial to use TGF-β1 as an anti-fibrotic target and thus selective blockade of downstream 
mediators to TGF-β1 signaling may represent an alternative approach.  
1.1.5.  Experimental model of systemic sclerosis 
Several experimental animal models of skin fibrosis, such as tight skin (Tsk) mouse, 
Tsk2 mouse, and bleomycin (BLM) induced murine SSc, sclerodermatous graft versus-host 
disease (Scl-GvHD) mouse exogenous injections of TGF-β1 and CTGF-induced murine 
fibrosis model have been reviewed in detail (Yamamoto 2010). The features of those 
experimental models are summarized in Table 1. The BLM mouse model is a well-
established model of SSc in which mice develop localized skin fibrosis after repeated 
intradermal or subcutaneous injections of BLM into the shaved back skin (Yamamoto, 
Takagawa et al. 1999). BLM is a chemotherapeutic agent and exhibits skin and lung fibrosis 
as a common side effect. In this mouse model, the sequence of histopathological changes in 
the skin closely resembles to that seen in SSc including upregulated TGF-β1 expression and 
accumulation of α-SMA expressing myofibroblasts (Yamamoto 2006). In vitro, BLM 
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upregulates collagen and induces TGF-β1 mRNA expression in cultured rat lung (Yamamoto 
and Nishioka 2005) and human skin fibroblasts (Yamamoto, Eckes et al. 2000). Also, BLM 
enhances gene expression of ECM proteins as well as fibrogenic cytokines which may 
contribute to the induction of fibrosis. Interestingly, superoxide and hydroxyl radicals are 
generated after bleomycin administration (Yamamoto and Katayama 2011). P47phox-deficient 
mice exhibited lower level of free radical production through NADPH-oxidase and reduced 
bleomycin-induced lung fibrosis (Varga and Abraham 2007). 
Table 1: Animal models of systemic sclerosis 
 
 
1.2.  Reactive oxygen species  
1.2.1.  Sources of reactive oxygen species generation  
ROS are small chemically reactive molecules derived from oxygen with one or more 
unpaired electrons in the outer orbitals. They are classified into the following oxygen 
radicals: superoxide (O2•-), hydroxyl (OH•), peroxyl (RO2•), alkoxyl (RO•) and non-radicals 
such as hypochlorous acid (HOCl), ozone (O3), and hydrogen peroxide (H2O2). The non-
radicals are either oxidizing agent and or easily converted into radical forms. Long time ago, 
it was known that ROS have an essential role in the host defense mechanism by killing 
microbes or inactivating microbial virulence factors but recently, another properties have 
been emerged. ROS has been showed to participate in virtually all intracellular cellular 
signaling pathways such as inhibition of phosphatases, activation of kinases, angiogenesis 
and regulation of matrix metalloproteinases (Scandalios 2005, Valko, Leibfritz et al. 2007, 
Armitage, Wingler et al. 2009). Excessive production of ROS is involved in many 
pathological disorders such as carcinogensis, neurodegneration, atherosclerosis, ischemia, 
 
Mouse model    
                                                          Characters 
Skin fibrosis      Skin sclerosis      Lung fibrosis        Increased collagen       TGF-β1 
                                                                                                                                                                                   upregulation   
BLM-induced Mouse + + + + + 
TSK mouse + - + + + 
Scl-GvHD mouse + - + + + 
Growth factor injected 
mouse 
+ - + + + 
UCD-200 chicken + + + + + 
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(Holmstrom and Finkel 2014). ROS can modulate redox-reactive Cys residues through 
switching between oxidation and reduction. Oxidation of theses residues forms reactive 
sulfenic acid (SOH) which leads to conformational changes in target proteins. Subsequently, 
SOH forms disulfide bonds or is further oxidized to sulfinic (-SO2H) or sulfonic (-SO3H) 
acid (Babalola, Mamalis et al. 2014). These intermediate products can be reversed by 
reducing system including glutathione (Gth) and the thioredoxin (Trx) system. Both Trx and 
GSH redox systems have been shown to regulate cell signaling and metabolic pathways 
differently and independently during diverse stressful conditions (Chung, Wang et al. 2013, 
Babalola, Mamalis et al. 2014). Furthermore, redox states of Trx and GSH have been used as 
indicators of oxidative stress and are described to physically interact with different 
transcription factors (Holmstrom and Finkel 2014). It should be noted that many transcription 
factors seem to be redox-sensitive such as activator protein 1 (AP1) and Nuclear factor 
(erythroid-derived 2)-like 2 (Nrf2) (Liu, Colavitti et al. 2005, Pendyala and Natarajan 2010).  
1.2.3.  Antioxidant studies in vitro, vivo and clinical trials 
Cells have the ability to eliminate excess of ROS by various antioxidant defense 
systems either enzymatically by superoxide dismutase (SOD), catalase, peroxiredoxins and 
cytosolic glutathione peroxidase (GSH) or by non-enzymatic scavenging compounds such as 
tocopherols (vitamin E), ascorbate (vitamin C), glutathione, selenium and carotene (Valko, 
Leibfritz et al. 2007). The localization of these antioxidant enzymes is cell type specific. The 
most important of these antioxidant enzymes is superoxide dismutase, which exists in three 
major cellular forms: copper zinc (CuZnSOD, SOD1) in the cytosol, manganese (MnSOD, 
SOD2) in the mitochondria, and extracellular (SOD3) in the interstitial spaces of tissues and 
extracellular fluids of many cell types and tissues  (Nozik-Grayck, Suliman et al. 2005, 
Valko, Leibfritz et al. 2007). Other antioxidant enzymes play an important role in the 
regulation of cellular H2O2 like GSH-Px in cytoplasm and catalase which is mainly found in 
peroxisomes (Vives-Bauza, Starkov et al. 2007). SOD catalyzes two molecules of superoxide 
to produce H2O2 by a chemical reaction called dismutation. Catalase and GSH convert 
hydrogen peroxide into water. In the presence of iron, superoxide and H2O2 react to generate 
hydroxyl radicals. Neutrophils in inflamed areas produces hypochlorous acid (HOCl), H2O2 
and chloride by the phagocyte-specific enzyme myeloperoxidase (MPO) (Winterbourn and 
Hampton 2008). 
Many studies reported that SSc patients exhibit a reduced total antioxidant activity, 
antioxidative vitamins (ascorbic acid, 𝛼𝛼-tocopherol, and 𝛽𝛽-carotene), and minerals (zinc, 
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selenium) (Sfrent-Cornateanu, Mihai et al. 2008). Recently, attempts have been made to find 
antioxidative molecules either nutritional or pharmacological ones to neutralize or reduce the 
oxidative stress in cells that are involved in SSc pathogenesis, in particular in endothelial 
cells and proliferating fibroblasts. For instance, N-acteyl-cysteine (NAC) has been used as an 
antioxidant, and its effect in SSc was examined in various studies (Yildirim, Kotuk et al. 
2005) (Failli, Palmieri et al. 2002). Treatment of dermal fibroblast from SSc patients with 
NAC reduced the generation of H2O2, collagen type I expression and cell proliferation. Other 
natural antioxidants are now emerging in the field, such as polyphenols from green tea 
extracts, namely epigallocatechin-3-gallate (EGCG). TGF-β1-induced collagen, fibronectin 
and α-SMA expression was down-regulated after the treatment with EGCG in SSc fibroblasts 
(Dooley, Shi-Wen et al. 2010), indicating its potential anti-fibrotic effects. Interestingly, 
EGCG can beneficially inhibit ROS production in vivo models (Pini, Shemesh et al. 2010).  
Additionally, many antioxidants mechanisms are involved in the reduction of 
intracellular ROS production. For example, Nrf2 is activated in response to oxidative stress 
which results in the induction of many cytoprotective genes. Interestingly, Nrf2-deficient 
mice displayed the upregulation of ECM genes in response to hypoxia (Saw, Yang et al. 
2014), and increased BLM-induced lung fibrosis (Cho, Reddy et al. 2004) has been also 
observed. Nonetheless, Nrf2 exerts a crucial role in attenuating pulmonary fibrosis through 
the improvement of antioxidant capacity in mice (Kikuchi, Ishii et al. 2010). Overall, Nrf2 
might be targeted as a potential therapy in SSc.  
To date, several clinical trials have been reported that the administration of 
antioxidants might be harmful rather than beneficial and this may be due several reasons 
including lack of specificity, low oral bioavailability, potency, poor trial design, duration of 
administration, or lack of relevant biomarkers of oxidation (Galli, Battistoni et al. 2012, 
Ciofu and Lykkesfeldt 2014, Grygiel-Gorniak and Puszczewicz 2014). Therefore, alternative 
strategies targeting the enzyme responsible for ROS generation in such fibrotic disease (likely 
SSc) by developing specific Nox inhibitors are currently emerging. Such agents could 
represent novel antifibrotic therapeutic strategies.  
1.3.  NADPH oxidases (NOXs) 
1.3.1.  The family of NADPH oxidases 
The nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (Nox) was first 
discovered in phagocytic cells. Currently, seven distinct Nox isoforms have been identified in 
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human: Nox1-5 and dual oxidase: Duox1-2. All Nox isoforms consists of six highly 
conserved transmembrane domains (TM). These domain including two heme binding regions 
and the cytoplasmic COOH terminus that contains the binding sites for both Flavin Adenine 
Dinucleotide (FAD) and NADPH and N-terminus (Geiszt 2006, Bedard and Krause 2007). 
The classical phagocytic Nox isoform consists of two plasma membrane associated proteins, 
the catalytic subunit gp91phox (namely Nox2) together with the regulatory units p22phox 
forming cytochrome b558 complex. The remaining oxidase components reside in the cytosol 
and include other regulatory subunits p40phox, p47phox, p67phox and the small GTPase Rac1/2 
(Figure 5). Upon stimulation, p47phox is phosphorylated and forms a complex with the other 
cytosolic subunits. This complex translocate to the cell membrane where it assembles with 
cytochrome b558 to constitute the active enzyme which transfers electrons from the reduced 
substrate NADPH to FAD, then to the first and second heme redox centers and finally to 
molecular oxygen to produce superoxide, however this key catalytic subunit also requires the 
assembly of the five subunits for activation (Cross and Segal 2004). All Nox isoforms release 
different type of ROS whereas Nox1, 2 and 5 produce superoxide while Nox4 and Duox1/2 
produce mainly hydrogen peroxide. Notably, the amount and duration of ROS production is 
significantly less than that of the phagocyte Nox enzyme (Kawahara and Lambeth 2007). 
These variations may influence the activation mechanisms of individual isoforms. 
Additionally, it has been reported that all Nox isoforms bind to one or more cytosolic or 
regulatory proteins which essential for their function (Li and Shah 2003, Bedard, Lardy et al. 
2007). Nox1 activity requires p22phox, Noxo1 (or possibly p47phox in some cases) and Noxa1, 
and the small GTPase Rac. Nox2 requires p22phox, p47phox, p67phox, and Rac. Nox3 requires 
p22phox and Noxo1. In contrast, Nox4 requires p22phox in some cells but usually it is 
constitutively active without the requirement for other subunits, this isoform is discussed in 
details in the chapter 1.4. Unlike Nox1-Nox4, Nox5, Duox1/2 are activated by Ca2+ and do 
not appear to require other activator or organizer subunits (Rizvi, Heimann et al. 2012) 
(Figure 5). 
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phagocytic cells, the subcellular distribution depends on the cell type. For example, in smooth 
muscle cells, Nox2 is localized with the perinuclear cytoskeleton. In neurons, Nox2 is 
localized in the membranes of synaptic sites (Tejada-Simon, Serrano et al. 2005). Nox4 is 
suggested to be localized in intracellular membranes. 
Table 2. Tissue distribution of Nox family NADPH oxidase  
Enzyme Other 
names 
Regulatory 
factors 
High level of 
expression 
Intermediate or low expression 
Nox1 Mox1, 
gp91-2 
Noxo1,Noxa1 
and p22phox 
Colon Aortic smooth muscle, uterus, prostate, 
endothelium, osteoclasts and retinal 
pericytes 
Nox2 gp91phox, 
CYBB 
p22phox, p47phox, 
p67phox, p40phox, 
Rac1-2 
Phagocytes Blymphocytes, neurons, endothelium 
cardiomyocytes, hematopoietic stem cells 
,skeletal muscle, hepatocytes, smooth 
muscle cells 
Nox3 gp91-3 Noxo1,Noxa1?? Inner ear Sensory epithelia, fetal spleen, brain 
Nox4 Renox , 
KOX, 
KOX 
p22phox, 
Poldip2?? 
Kidney, blood vessels, 
fibroblasts, 
Osteoclasts, smooth muscle cells,  
hematopoietic stem cells, keratinocytes, 
melanoma cells, neurons 
Nox5 - Calcium Lymphoid tissue, 
testis 
Endothelium, smooth muscle, pancreas, 
placenta, ovary, uterus, stomach, various 
fetal tissues 
Duox1 ThOx1 Calcium Thyroid Airway epithelia, tongue epithelium, 
cerebellum, testis 
Duox2 ThOx2 Calcium Thyroid Salivary and rectal glands, gastrointestinal 
epithelia, airway epithelia, uterus, gall 
bladder, pancreatic islets 
 
1.4.  NADPH oxidase 4 (Nox4) 
1.4.1.  Structure, function and regulation of Nox4 
The human Nox4 gene is located on chromosome 11. Nox4 is a 67 kDa protein 
sharing 39% amino acid identity with Nox2. Nox4 comprises six membrane-α-helices 
connected by five loops, namely loops A-E, and a dehydrogenase (DH) domain that contains 
the binding sites for FAD and NADPH as illustrated in Figure 6. The A,C and E-loops face 
the outer space of the membrane while B and D loops Face the cytoplasm side of the 
membrane where DH domain is located (Yoshida and Tsunawaki 2008). Unlike other Nox 
isoforms, Nox4 is constitutively active and it produces mainly H2O2 through the highly 
conserved histidine residue in the E-loop (Takac, Schroder et al. 2011) and superoxide 
(Boudreau, Emerson et al. 2009). According to the recent model proposed by Nisimoto 
(Nisimoto, Diebold et al. 2014), two molecules of oxygen were sequentially reduced to 
superoxide then two molecules of superoxide dismutased spontaneously by SOD into H2O2 
and oxygen.  
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canonical protein (65kDa) during the posttranslational maturation, increasing its molecular 
weight (75-80 kDa). Unlike other Nox isoforms, Nox4 is solely regulated via its expression 
level, and its activation depends on its interaction with p22phox (Ambasta, Kumar et al. 2004). 
Nevertheless, recent studies have demonstrated that the modulation of Nox4 activity occurred 
by proteins such as the DNA polymerase-delta interacting protein 2 (Poldip2)(Lyle, 
Deshpande et al. 2009), tyrosine kinase substrate 5 (TKs5)(Diaz, Shani et al. 2009) the 
protein disulfide isomerase (PDI) (Janiszewski, Lopes et al. 2005), although the exact 
mechanisms in SSc cells need to be elucidated. Several cytokines and growth factor have 
been reported to modulate Nox4 expression such as TGF-β1, TNF-α, PDGF and LPS in 
different cell types. Additionally, various transcription factors including Smad2/3 (Sturrock, 
Cahill et al. 2006), E2F (Zhang, Sheppard et al. 2008), Nrf2 (Pendyala, Moitra et al. 2011), 
NF-κB (Manea, Tanase et al. 2010), HIF-1α (Diebold, Petry et al. 2010, Lassegue and 
Griendling 2010), Sp3 and Sp1 (Katsuyama, Hirai et al. 2011), c-jun and STAT3 (Manea, 
Tanase et al. 2010) have been identified to bind to the Nox4 promoter thereby regulating its 
expression. Nox4 is consistently upregulated by TGF-β1 in all cell types tested (Brown and 
Griendling 2009, Lassegue and Griendling 2010). Nox4 may also be involved in the 
regulation of redox-sensitive pathways (MAPK, TGF-β1, Nrf2/KEAP1) through hydrogen 
peroxide (H2O2) production which has been reported to act as a second messenger in 
physiological conditions (Konior, Schramm et al. 2014). Moreover, histone deacetylases 
(Siuda, Zechner et al. 2012), histone modification (Sanders, Liu et al. 2015) and miRNAs 
(Varga, Kupai et al. 2013) have been proposed to affect Nox4 expression at the 
posttranscriptional level. 
1.4.2.  Tissue distribution and subcellular localization 
Nox4 displays a wide tissue expression suggesting a number of diverse functions 
ranging from oxygen sensing to fibrotic processes. Nox4 mRNA is essentially found in renal 
tissue (fetal and adult) and in diverse tissues (pancreas, lung, placenta, ovary, testis, muscles 
and fetal tissues in general). At the cellular level, Nox4 mRNA is found in various cell types 
including smooth muscle cells, endothelial cells, fibroblasts, adipocytes, cardiomyocytes, 
neurons, and keratinocytes. Nox4 is also found in hematopoietic stem cells (Piccoli, Ria et al. 
2005), osteoclasts(Yang, Zhang et al. 2004), melanoma cells (Brar, Kennedy et al. 2002), 
neurons (Kleinschnitz, Grund et al. 2010), keratinocytes (Chamulitrat, Stremmel et al. 2004), 
adipocyte (Kanda, Hinata et al. 2011), embryonic stem cells (Bartsch, Bekhite et al. 2011), 
chondrocytes (Grange, Nguyen et al. 2006), hepatic stellate cells (Ikeda, Ishii et al. 2011), 
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epithelial cells (Carnesecchi, Deffert et al. 2011), and podocytes (Piwkowska, Rogacka et al. 
2011).  
Although Nox4 has been reported to be localized at intracellular membranes even its 
subcellular localization is still in debate. It has been described in the endoplasmic reticulum 
(ER) of cardiomyocyte where Nox4 interacts with the protein disulfide isomerase (PDI), in 
the nuclei of human airway smooth muscle cells, in the plasma membrane of HEK 293 cells, 
and in the mitochondria of mesangial cells of the kidney cortex (Janiszewski, Lopes et al. 
2005). In other studies, Nox4 was also described to translocate to the plasma membrane after 
interacting with its partner component p22phox in different cell types (Laurindo, Fernandes et 
al. 2008, von Lohneysen, Noack et al. 2008). It has been hypothesized that the specific 
physiological role may depend on its intracellular localization and/or its ability to produce 
H2O2, a stable and diffusible signaling molecule (Takac, Schroder et al. 2011). Notably, the 
localization of Nox4 in intracellular membranes is dependent upon the presence of signal 
sequences specific to the ER (Chen, Kirber et al. 2008), to mitochondria (Ago, Kuroda et al. 
2010) and to the nucleus (Matsushima, Kuroda et al. 2013). Alternative splicing of Nox4 
mRNA, post-translational modifications has been recently suggested to direct Nox4 synthesis 
in different subcellular compartments (Anilkumar, San Jose et al. 2013). However, the 
intracellular localization of Nox4 may influence its downstream targets.  
1.4.3.  Physiological and pathological role of Nox4  
Nox4 has an important role in a variety of physiological and pathological conditions 
in different cell types. It has been showed that Nox4 play a physiological role in anti-
inflammatory response in neurons, senescence of human endothelial cells, oxygen sensing in 
HEK293 cells, migration in vascular smooth muscle cells, insulin regulation in adipocytes; 
proliferation in preadipocytes, osteoclastogensis and bone resorption in osteoclasts, and 
apoptosis in cerebral microvascular endothelial cells (Guo and Chen 2015).  
Nevertheless, several studies reported the involvement of Nox4 activation in various 
pathological conditions, notably cardiovascular disease, diabetes, atherosclerosis, kidney and 
lung fibrosis. In both fibroblasts and smooth muscle cells, Nox4 mRNA is increased by 
hypoxia, and knockdown of Nox4 decreases cell proliferation (Li, Tabar et al. 2008, Ismail, 
Sturrock et al. 2009). TGF-β1 also induces Nox4 expression and ROS production in 
HPASMC (Sturrock, Cahill et al. 2006). In addition, Nox4 is involved in TGF-β1-induced 
epithelial-to-mesenchymal transition and migration of breast epithelial cells. Interestingly, 
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knock-down of Nox4 by siRNA Nox4 gene ameliorates bleomycin-induced pulmonary 
fibrosis in mice by decreasing ECM protein accumulation (Hecker, Vittal et al. 2009).  
1.4.4.  Pathological role of Nox4 in fibrotic disorders  
Nox enzymes have been implicated in the pathogenesis of fibrosis at different 
pathological conditions such as diabetic nephropathy, pulmonary fibrosis, cardiac 
hypertrophy, and pancreatic fibrosis (Barnes and Gorin 2011, Bhattacharyya, Wei et al. 
2011). Indeed, several growth factors which participate in SSc pathogenesis including 
TGF-β1, PDGF, angiotensin II and endothelin 1 have been shown to modulate the expression 
of  Nox protein, in particular Nox4 (Gorin, Ricono et al. 2003, McCann, Dusting et al. 2008, 
Amara, Goven et al. 2010, Kim, Kim et al. 2011). For example, in heart, TGF-β1 stimulates 
Nox4-mediated generation of ROS leading to increased expression of ECM proteins such as 
collagen and fibronectin (Rocic and Lucchesi 2005). Nox4 is upregulated in lungs of patients 
with idiopathic pulmonary fibrosis (IPF) as well as in kidney and liver fibrosis (Amara, 
Goven et al. 2010, Bondi, Manickam et al. 2010). Nox4 expression is robustly increased in 
pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and also in rodent 
models. Inhibition of Nox4 using genetic or pharmacological approaches prevents lung 
fibrosis (Hecker, Vittal et al. 2009) and suggests a prominent role for Nox4 in the 
pathogenesis of pulmonary fibrosis. Additionally, Nox4-derived ROS reversibly inactivate 
cysteine-dependent serine/threonine protein tyrosine phosphatases (PTPs) resulting in the 
increased activity of various kinases including c-jun amino-terminal kinase (JNK), mitogen-
activated protein kinases (MAPKs), Janus kinase (JAK), c-Src, and extracellular signal-
regulated kinases (ERKs) (Anilkumar, Weber et al. 2008). Furthermore, fibroblasts isolated 
from lungs of patients with IPF generated increased H2O2 in response to TGF-β1, and induced 
death of the respiratory epithelial cells (Sakai and Tager 2013). In vivo, p47phox-deficient 
mice are protected against bleomycin-induced lung and liver fibrosis (Manoury, Nenan et al. 
2005, Levin, Petrasek et al. 2012). Indeed, Nox has been reported to be involved in many 
skin disorders as hypertrophic scars and keloids fibroproliferative disorder in which 
Nox  upregulates pyridinoline cross-link formation in collagen (Wan and Evans 1999, Wan, 
Wu et al. 2002, De Felice, Wilson et al. 2009). Nox4-dependent generation of ROS has 
recently been postulated to be involved in the fibrotic process in SSc. However, experimental 
findings supporting the involvement for Nox4 in the fibrotic progress in SSc are still lacking.  
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1.5.  NADPH oxidase inhibition  
Given the fact that oxidative stress is involved in the pathogenesis of many fibrotic 
diseases, many efforts have been dedicated to discover and develop effective isoform-specific 
Nox inhibitors (Table 3). Inhibition of Nox could be achieved through several strategies: by 
decreasing gene or protein expression via siRNA techniques; by inhibiting the assembly of 
the cytosolic component that may prevent the activation of Nox enzymes, by post-
translational modification of the oxidase itself and/or its upstream activators by disrupting 
Nox-mediated cell signaling, by competitive inhibition of Nox enzymes with molecules 
mimicking NADPH structure; and by inhibiting the phosphorylation of the p47phox subunit 
(Altenhofer, Kleikers et al. 2012, Schramm, Matusik et al. 2012, Rodino-Janeiro, Paradela-
Dobarro et al. 2013, Babalola, Mamalis et al. 2014) . 
 
Table 3. List of the most common NADPH oxidase inhibitors  
Name  Proposed mechanism of  action  Reference 
Apocynin Inhibits association of p47phox with membrane-
bound heterodimer 
(t Hart, Simons et al. 1990) 
DPI substracts electrons from FAD and then 
prevents electron flow through the 
falvocytochrom and block the activity 
(Stuehr, Fasehun et al. 
1991) 
GKT137831/ 
GKT136901 
They might act as a competitive inhibitor to 
Nox enzyme but the mechanism is still under 
investigation 
(Gianni, Taulet et al. 2010) 
N-acetyl-L-cysteine Increases SOD2 activity caused decreased 
oxidative stress 
(Moon, Kang et al. 2006) 
(PHTE)(2)NQ 
(a tellurium-based catalyst 2,3 
bis 
(phenyltellanyl)naphthoquino
ne) 
Reduces the intracellular level of ROS, reveals  
cytotoxic activity in hyperproliferative 
fibroblasts 
(Marut, Kavian et al. 2012) 
Pulmbagin Inhibits Nox-derived ROS; the mechanism is 
still unknown 
(Ding, Chen et al. 2005) 
VAS2870 Directly interacts with the Nox complex and 
inhibit its assembly 
(Tsai and Jiang 2010) 
 
Diphenylene iodonium (DPI) is very potent inhibitor of NADPH oxidases. It inhibits 
NADPH oxidases and other FAD-containing enzymes (Wind et al., 2010). Notably, it was 
found that DPI also inhibits the production of ROS in a variety of other cell types including 
white blood cells, epithelial cells of the gut and fibroblast that express different Nox isoforms 
as Nox1, Nox2 and Nox4. As a rule of thumb, if the signal is not blocked by DPI, this usually 
means that the ROS are not derived from Nox (Maghzal, Krause et al. 2012). Thus, DPI is a 
useful tool for studying Nox enzymes in vitro. Thus, interpretation of in vitro results with 
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DPI needs to be combined with data from other techniques such as gene ablation of Nox 
isoforms. In a BLM-lung fibrosis model, administration of DPI 1 mg/kg resulted in a 
decrease of superoxide anion production measured by lucigenin enhanced 
chemiluminescence, as well as attenuation of lung and intestinal injury (Abdelrahman, 
Mazzon et al. 2005). Caution should be taken when using DPI for inhibiting ROS production 
in vivo as it lacks specificity and has cytotoxic effects at certain doses thereby limiting the 
use of DPI in clinical trials. Therefore, only a small number of studies have been published in 
which the potential beneficial effects of DPI was examined in in vivo animal models. 
Apocynin is an orally natural active agent that can block NADPH oxidase assembly 
but requires a reaction with peroxidase for its activation, and therefore does not work 
immediately (Abdelrahman, Mazzon et al. 2005). Apocynin reduces ROS production when 
tested in animal models of arthritis, asthma and hypertension (Schramm, Matusik et al. 2012). 
In addition, apocynin acts to lower ROS levels in non-phagocytic cells by functioning as an 
antioxidant rather than a Nox inhibitor and therefore its use is currently limited. By contrast, 
apocynin acts at the level of the p47phox subunit thereby preventing its association with the 
membrane-bound heterodimeric Nox-p22phox complex (Drummond, Selemidis et al. 2011).  
VAS2870 and VAS3947 (Vasopharm) are cell permeable thiotriazolo pyrimidine 
compounds that are reported as rapid and reversible inhibitors of NADPH oxidase activity. 
VAS2870 has also been shown to efficiently reduce ROS generation in vitro. It was effective 
in inhibiting PDGF-stimulated cell migration and PMA-dependent stimulation of superoxide 
production from NADPH oxidase in human phagocytes (ten Freyhaus, Huntgeburth et al. 
2006, Wind, Beuerlein et al. 2010). However, the mechanism has not yet been fully 
established. There is currently no information on the in vivo effects of VAS2870 in either 
normal or diseased animal models. GKT137831 and GK136901 are very recent Nox1/4 
inhibitors (Genkyotex) and have drawn considerable attention. Indeed, recent reports have 
demonstrated that NADPH oxidase activity, p38MAP kinase activity as well as TGF-β1-
induced fibronectin generation were attenuated in mouse proximal tubular cells after 
GKT136901 administration (Sedeek, Callera et al. 2010). Similar, it has been shown that 
GKT137831 attenuated hypoxia-induced pulmonary vascular cell proliferation in mice, 
suggesting its value in pulmonary hypertension (Green, Murphy et al. 2012). Interestingly, 
Hecker et al. demonstrated that myofibroblasts phenotype was reversed following treatment 
with the Nox4-selective small-molecule inhibitor GKT137831 (Hecker, Logsdon et al. 2014). 
GKT137831 and GK136901 have unique features more than other identified Nox inhibitors. 
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They display high oral bioavailability, lack of off-target effects and show a good safety 
profile in vivo. Therefore, GKT137831, has been applied in phase II clinical studies in 
patients with diabetic nephropathy revealing promising data in several other disease models, 
including atherosclerosis (Di Marco, Gray et al. 2014), idiopathic pulmonary fibrosis 
(Hecker, Cheng et al. 2012) and liver fibrosis (Jiang, Chen et al. 2012). 
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2.  Aim of the study 
SSc is a complex chronic disease with a high rate of morbidity and mortality without any 
effective therapies to date. A better understanding of the molecular mechanism that underlies the 
pathogenesis of SSc will provide a novel approach for an effective treatment for this disease. 
TGF-β1 appears as a master regulator not only of collagen synthesis and pathological 
extracellular matrix remolding but also being responsible for fibroblast activation and 
differentiation into a profibrotic myofibroblast phenotype. In addition, there is growing evidence 
that oxidative stress may also contribute to tissue damage in SSc. One of the major sources of 
ROS generation is the multicomponent membrane-bound Nox. However, the precise molecular 
interplay between TGF-β1 and NADPH oxidase remains largely unexplored in human dermal 
fibroblasts. Therefore, the present study has been performed to explore the role of NADPH 
oxidase in the context of TGF-β1 signaling within fibrotic disorders especially skin fibrosis.  
According to our preliminary data we have hypothesized that NADPH oxidase 4 (Nox4) 
represents an intracellular nodal point that orchestrates collagen synthesis, differentiation of 
dermal fibroblasts into a profibrotic myofibroblast phenotype, and thus dermal fibrosis. To verify 
that hypothesis we set up the following specific aims: 
Aim 1: To investigate the expression of Nox4 and related Nox isoforms and cytosolic co-factors 
in both human dermal fibroblasts and scleroderma fibroblasts. 
Aim 2: To determine whether Nox4 modulates activation and differentiation of fibroblasts to 
myofibroblasts in response to TGF-β1. 
Aim 3: To evaluate whether pharmacological or genetic inhibition of Nox4 suppress dermal 
fibroblasts differentiation into a profibrotic myofibroblast phenotype. 
Aim 4: To analyze whether the neuropeptide α-melanocyte stimulating hormone (α-MSH) has an 
inhibitory effect on TGF-β1-mediated Nox4 expression. 
Aim 5: To determine whether pharmacological Nox inhibitors affect experimentally induced 
skin fibrosis in a bleomycin animal model of scleroderma 
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3.  Materials and Methods 
3.1.  Materials  
3.1.1.  Chemicals  
Table 4: List of chemicals and biochemical reagents used in this study 
Chemical  Manufacture 
Acetic acid  Sigma-Aldrich, Taufkirchen 
Acetone  Sigma-Aldrich, Taufkirchen 
Acrylamide Carl Roth, Karlsruhe 
Agarose  Biozym, Hessisch Oldendorf 
Ammonium persulfate (APS) Sigma-Aldrich, Taufkirchen 
Bromophenol blue Merck, Darmstadt 
Chloroform  Merck, Darmstadt 
DAPI  Sigma-Aldrich, Taufkirchen 
DMSO (Dimethylsulfoxide)  Sigma-Aldrich, Taufkirchen 
DPBS w/o Ca2+ or Mg2+ Merck, Darmstadt 
ECL   Carl Roth, Karlsruhe 
EDTA Applichem, Darmstadt 
Ethanol   Sigma-Aldrich, Taufkirchen 
EGTA Sigma-Aldrich, Taufkirchen 
Ethidium bromide Sigma-Aldrich, Taufkirchen 
Glycine Carl Roth, Karlsruhe 
GoTaq polymerase  Promega, Mannheim 
HCl Carl Roth, Karlsruhe 
Hydrogen peroxide solution, 30% Carl Roth, Karlsruhe 
Isopropyl alchol Carl Roth, Karlsruhe 
KH2PO4 MERCK, Darmstadt 
L-Glutamine  Sigma-Aldrich, Taufkirchen 
Lipofectamin 2000   Invitrogen, UK 
Luciginin Enzo, Lörrach 
Methanol  Carl Roth, Karlsruhe 
DABCO / Mowiol 4-88  Carl Roth, Karlsruhe 
NADH  Sigma-Aldrich, Taufkirchen 
NaHCO3  MERCK, Darmstadt 
NaH4Cl MERCK, Darmstadt 
NaCO3 Carl Roth, Karlsruhe 
Nitrocellulose  Millipore, Bedford, MA, USA 
Penicillin/Streptomycin (10,000 U/ml, 10 mg/ml) Gibco, Darmstadt 
Protease inhibitor cocktail tablets  Roche Diagnostics GmbH, Mannheim 
RedSafe iNtron biotechnology, Freiburg 
RNAse free Water   Qiagen, Hilden 
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Sodium Dodecylsulfate (SDS) Sigma-Aldrich, Taufkirchen 
Sucrose  Sigma-Aldrich, Taufkirchen 
SYBR Green Rox Mix  Thermo Fisher Scientific, Epsom, Surrey, UK 
TEMED Sigma-Aldrich, Taufkirchen 
Triton X-100  Sigma-Aldrich, Taufkirchen 
Tris (HCl) Carl Roth, Karlsruhe 
Triton-X-100  Sigma-Aldrich, Taufkirchen 
Trizol reagent  iNtron biotechnology, Freiburg 
Trypsin 0.25 % Gibco, Karlsruhe 
Tween 20  Sigma-Aldrich, Taufkirchen 
Trizol (peqGOld-Trifast)  PeqLab, Erlangen, Deutschland 
Trypan blue  Sigma-Aldrich, Taufkirchen 
β-Mercaptoethanol  Carl Roth, Karlsruhe 
 
3.1.2.  Stimulants and pharmacological inhibitors  
Table 5: List of stimulants and pharmacological inhibitors used in this study 
Name Manufacture  
α-MSH  Calbiochem, Schwalbach 
Actinomycin D Sigma-Aldrich, Taufkirchen 
Bleomycin Sigma-Aldrich, Taufkirchen 
Cycloheximide Sigma-Aldrich, Taufkirchen 
Diphenyleneiodonium Sigma-Aldrich, Taufkirchen 
SIS3  Calbiochem, Schwalbach 
TGF-β1 (Human)  Peprotech, Hamburg 
TGF-β1 (murine)  eBioscience, Frankfurt am Main 
VAS2870 Sigma-Aldrich, Taufkirchen 
 
 
3.1.3.  Media and Buffers 
3.1.3.1.  Sera 
Table 6: List of sera used in this study 
Name  Manufacturer 
Bovine Serum Albumin (BSA) 
Fetal Bovine Serum (FBS) 
Normal goat serum                                       
PAA, Pasching, Austria 
PAA, Pasching, Austria 
Dako, Glostrup, Denmark 
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3.1.3.2.  Media  
All cell culture media used in this study were purchased from Gibco (Karlsruhe) 
• Dulbecco's Modified Eagle Medium (Advanced DMEM/F-12) was supplemented with  
2 mM L-glutamine, 5 % FCS, 1 % penicillin (50 U/ml) and streptomycin (50 µg/ml). 
• Roswell Park Memorial Institute Medium (RPMI1640) was supplemented with  
2 mM L-glutamine, 10 % FCS, 1 % penicillin (50 U/ml) and streptomycin (50 µg/ml). 
 
3.1.3.3.  Buffers 
Table 7: List of buffers and solutions used in this study 
Name Components  
 
DNA loading buffer (6x)  
 
0.25  % Bromophenol blue 
0.25  % Xylene cyanol 
30.0 % Glycerol 
100.0 mM EDTA  
Adjusted with HCl to pH 8.0 
 
Blotting buffer  
25 mM Tris base 
192 mM glycine 
10 % methanol 
pH adjusted with HCl to 7.6 
 
Laemmli sample buffer (2x) 
 
100 mM Tris-HCl, pH 6.8 
4 % SDS 
20 % Glycerol 
0.2 % Bromophenol blue 
10 % β-Mercaptoethanol 
H2O up to 10 ml 
 
Lysis buffer (Immunoprecipitation buffer) 
  
50 mM HEPES, pH adjusted to 7.5 
150 mM NaCl 
10 % Glycerol 
1 % Triton-X-100  
1.5 mM MgCl2 
1 mM EGTA 
100 mM NaF 
10 mM Pyrophosphate 
 0.01 % NaN3  
H2O up to 100 ml 
pH 7.5 (adjusted using HCl)  
 
Phosphates buffered salt solution  
0.2 g KCl 
1.44 g Na2HPO4 
0.24 g KH2PO4 
H2O up to 1000 ml  
pH 7.4 (adjusted using HCl) 
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Running buffer 
25 mM Tris  
192 mM glycine 
1 % SDS 
 
Separating gel buffer 
1.5 M Tris HCl 
13.9 mM SDS  
H2O up to 500 ml 
pH 8.8 adjusted with HCl 
 
 
Stacking gel buffer 
1.25 M Tris HCl 
13.9 SDS  
H2O up to 500 ml 
pH 6.8 adjusted with HCl 
 
 
Stripping buffer 
 
7 M Guanidine hydrochloride solution  
50 mM Glycine (pH 10.8)  
0.05 mM EDTA  
100 mM KCl  
20 mM β-Mercaptoethanol 
TBE-buffer 8.9 mM Tris, pH (8.2) 
8.9 mM boric acid  
0.25 mM EDTA 
TBS-buffer 10 mM Tris, pH (7.5) 
150 mM NaCl 
 
TBST-buffer 
20 mM Tris, pH (7.5) 
500 mM NaCl 
0.05 % Tween 20 
0.2 % Triton X 
 
Transfer buffer 
25 mM Tris, pH (8.3) 
150 mM glycine 
10 % methanol 
 
3.1.4.  DNA ladder and protein markers 
 
Name Manufacture 
PageRuler TM Prestained Protein Ladder  
GeneRuler TM 50 bp DNA ladder 
GeneRuler TM 100 bp DNA ladder 
GeneRuler TM 1000 bp DNA ladder                                       
Thermo Scientific, Sankt Leon-Rot 
Fermentas, Sankt Leon-Rot  
Fermentas, Sankt Leon-Rot 
Fermentas, Sankt Leon-Rot 
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3.1.5.  Consumables and kits 
 
Name Manufacture 
BCA Protein Assay Reagent A and B 
RNeasy Mini Kit  
Revert AidTM cDNA Synthesis Kit 
procollagen I C-peptide ELISA  
Thermo Scientific, Sankt Leon-Rot 
Qiagen, Hilden 
Fermentas, Sankt Leon-Rot  
Takara Bio Europe, SAS 
3.1.6.  Primers  
Table 8: List of human PCR primers, amplicons sizes and references for endpoint RT-PCR and 
real-time RT-PCR. 
a) Endpoint RT-PCR primers 
Target 
Gene 
Forward/ 
Reverse  
Primer Sequence Product 
size 
Reference 
Nox1 Forward  5´TTCACCAATTCCCAGGATTGAAGTGGATG-3´ 230 Loughlin et al.,2010 
 Reverse            5´- GACCTGTCACGATGTCAGTGGCCTTGTCA-3´    
Nox2 Forward  5´-TGGGCTGTGAATGAGGGGCT-3´                          385 Jones et al.,1994 
 Reverse            5´ -TGACTCGGGCATTCACACAC-3´    
Nox4 Forward  5´-CTGGAGGAGCTGGCTCGCCAACGAAGG-3´  512 Loughlin et al.,2010 
 Reverse            5´-GATCATGAGGAATAGCACCACCAC-3´   
Nox5 Forward  5´-ATCAAGCGGCCCCCTTTTTTTCAC-3´   240 O'Brien et al., 2009 
 Reverse 5´-CTCATTGTCACACTCCTCGACAGC-3´    
Duox1 Forward  5´- ATCGCCACCTACCAGAACATC-3´  316 Cui et al.,2010 
 Reverse 5´-CAGTGCATCCACATCTTCAGC-3´    
p22phox  Forward  5´-GTTTGTGTGCCTGCTGGAGT-3´ 316 O'Brien et al., 2009 
 Reverse 5´-TGGGCGGCTGCTTGATGGT-3´    
p40phox  Forward  5´-GGACATAGCTCTGAATTACC-3´  174 Zhan et al., 1996 
 Reverse 5´-GGCATCGTGTTGTAGACCCT-3´    
p47Phox  Forward  5´-ACCCAGCCAGCACTATGTGT-3´  767 Jones et al.,1994 
 Reverse 5´-AGTAGCCTGTGACGTCGTCT-3´    
p67phox Forward  5´-CGAGGGAACCAGCTGATAGA-3´ 712 Jones et al.,1994 
 Reverse 5´-CATGGGAACACTGAGCTTCA-3´    
Poldip2 Forward 5´-TTTGGTGCCTACTCCATTGTGG-3´  65 This study 
 Reverse 5´-CAAGGTTCTCCAAACGGATACAG-3´    
Rac1 Forward  5´-GTAAAATACCTGGAGTGCT-3´  120 Cui et al.,2010 
 Reverse 5´-CAGCAGGCATTTTCTCTTCC-3´    
Rac2 Forward  5´-TCTCTGGCAAGCAGGAC-3´  165 Cui et al.,2010 
 Reverse 5´-GTGGAAGCATCTACCCG-3´    
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b) Real-time RT-PCR primers 
 
Target Gene Forward/ 
Reverse  
Primer Sequence Product 
size 
References 
Nox4  Forward  5´-CAGAAGGTTCCAAGCAGGAG-3´  128 Craige et al.,2011 
 Reverse            5´-GTTGAGGGCATTCACCAGAT-3´   
p22phox Forward  5´-TTTGGTGCCTACTCCATTGTGG-3´                          199 This study 
 Reverse            5´-TCATGTACTTCTGTCCCCAGCG-3´    
Poldip2 Forward  5´-TTTGGTGCCTACTCCATTGTGG-3´  65 This study 
 Reverse            5´-CAAGGTTCTCCAAACGGATACAG-3´    
Fibronectin1  Forward  5´- GTGCCCCACTCTCGGAATTC-3´  160 This study 
 Reverse 5´-CAGCAACAACTTCCAGGTCCC-3´    
α-SMA Forward  5´-GACCGAATGCAGAAGGAGAT-3´  98 Stegemann et al.,2013 
 Reverse 5´-CCACCGATCCAGACAGAGTA-3´    
SMAD3  Forward  5´- GAGTAGAGACACCAGTTCTA-3´  234 This study 
 Reverse 5´-TTTGGAGAACCTGCGTCCAT-3´    
COL(I)α1 Forward  5´- CAGCCGCTTCACCTACAGC-3´  250 Böhm et al.,2004 
 Reverse 5´- AATCACTGTCTTGCCCCAGG-3´    
COL(I) α2 Forward  5´- GATTGAGACCCTTCTTACTCCTGAA-
3´  
230 Böhm et al.,2004 
 Reverse 5´- GGGTGGCTGAGTCTCAAGTCA-3´    
β-actin Forward  5´- AAGGAGAAGCTGTGCTACGTC-3´  128 This study 
 Reverse 5´- AACCGCTCATTGCCAATGGTG-3´     
 
 
 
Table 9: List of murine PCR primers for real-time RT-PCR, amplicons sizes and references. 
 
Target Gene Forward/ 
Reverse  
Primer Sequence Product size References 
Fibronectin1 Forward  5´- ACCGACAGTGGTGTGGTCTA-3´  130 Hecker et al., 2009 
 Reverse            5´- CACCATAAGTCTGGGTCACG-3´   
α-SMA Forward  5´- GTCCCAGACATCAGGGAGTAA-3´                          102 Hecker et al., 2009 
 Reverse            5´- TCGGATACTTCAGCGTCAGGA-3´    
Nox4 Forward  5´- AGATGTTGGGGCTAGGATTG -3´  137 Hecker et al., 2009 
 Reverse            5´- TCTCCTGCTTGGAACCTTCT -3´    
COL(I)α1 Forward  5´- ACTGGE TACATCAGCCCGAACC-3´  145 Stegemann et al.,2013 
 Reverse            5´- GACATTAGGCGCAGGAAGGTC-3´    
COL(I) α2 Forward  5´- CAGGCCCAACCTGTAAACACC -3´  147 Stegemann et al.,2013 
 Reverse            5´- CTGAGTTGCCATTTCCTTGGAG -3´    
β-actin Forward  5´- TTGCTGACAGGATGCAGAAG-3´  147 Stegemann et al.,2013 
 Reverse            5´- TGATCCACATCTGCTGGAAG-3´    
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Table 10: List of targeted human siRNA sequences  
 
Target Gene           No:             Target siRNA Sequence 
SMAD3 Gene ID:4088        
            1 
  
 CAACAGGAAUGCAGCAGUG  
             2    GAGUUCGCCUUCAAUAUGA 
             3  GGACGCAGGUUCUCCAAAC                          
             4     UUAGAGACAUCAAGUAUGG  
Nox4 Gene ID:50507        
            1     
  
 ACUAUGAUAUCUUCUGGUA 
             2     GAAAUUAUCCCAAGCUGUA 
             3      GGGCUAGGAUUGUGUCUAA 
             4      GAUCACAGCCUCUACAUAU 
Non-targeting ON-TARGET plus control   UGGUUUACAUGUUGUGUGA 
 
* All siRNAs sequences and transfection reagent used in this study were purchased from Thermo 
Scientific Dharmacon, Germany.  
 
3.1.7.  Antibodies 
3.1.7.1.  Primary antibodies  
Table 11: List of primary antibodies used in this study 
Antibody Application Dilution  Catalog # Manufacture 
Rabbit anti- Nox4 Western Blotting  1:500 110-58849  Novus 
Rabbit anti- P22phox Western Blotting  1:1000 Ab-75941  Abcam 
Rabbit anti- Poldip2 Western Blotting  1:800 Ab-68663  Abcam 
Mouse anti-β-actin Western Blotting  1:1000 Sc-47778  Santa Cruz 
Mause anti-Vinculin  Immunofluorescence  1:100 Sc-5573 Santa Cruz 
Mouse anti-α-tubulin Western Blotting  1:1000 Sc-8035  Santa Cruz 
Mause anti-LAMP2 Immunofluorescence  1:200 Sc-8101 Santa Cruz 
Mause anti-Fibronectin 1 Western Blotting  1:400 Ab-6328 Abcam 
Mause anti-Fibronectin 1 Immunofluorescence  1:200 Ab-6328 Abcam 
Mause anti-α-SMA Western Blotting 1:100 M0851 Dako 
Mause anti-α-SMA Immunofluorescence  1:100 M0851 Dako 
Mause anti-PDI Immunofluorescence  1:100 NB300-517 Novus 
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3.1.7.2.  Secondary antibodies 
Table 12: List of secondary antibodies used in this study 
Antibody Application Dilution  Catalog # 
 
Manufactur 
Anti-rabbit IgG HRP-linked (ECL) Western Blotting  1:10.000 NA9340V GE Healthcare 
Anti-Mouse IgG HRP-linked (ECL) Western Blotting  1:10.000 NA9310V GE Healthcare 
Rabbit IgG isotype control Immunofluorescence 1:500 Sc-2027 Santa Cruz 
Mouse IgG isotype control Immunofluorescence  1:200 400101 BioLegend 
Alexa 488 goat-anti-rabbit  Immunofluorescence 1:1000 A-11070 Invitrogen 
Alexa 568 goat-anti-rabbit  Immunofluorescence 1:1000 A-11036 Invitrogen 
 
3.1.8.  Instruments and Laboratory equipment 
Table 13: List of laboratory equipments used in this study 
Name Company 
Analytical balance Sartorius 
Laminar flow station (Herasafe) Omnilab-Labcenter GmbH, Bremen 
Liquid nitrogen Tec-lab, Hessen 
Polyacrylamide gel electrophoresis chambers Biometra GmbH, Göttingen 
Agarose gel electrophoresis chambers Biorad, München 
Magnetic stirrer IKA,Labor technique  
Micropipette Pipetus,Hirschman 
pH-meter 766 Calimatic 
Microplate reader ELx808 BioTek, Bad Friedrichshall 
Sonicator IKA Bandelin 
Stander Power supply (P25T) Biometra, 
TissueLyser II Qiagen, Hilden, Deutschland 
Vortexer  Scientific Industries Inc., New York, USA 
Centrifuge Megafuge  Eppendorf, Hamburg 
Centrifuge MiniSpin plus Eppendorf, Hamburg 
Centrifuge: 5415R Eppendorf, Hamburg 
Thermocycler Eppendorf, Hamburg 
Thermomixer Eppendorf, Hamburg 
Geldocumentation system FUSION-FX7 Advance™, Peqlab, Erlangen 
Blotting chamber semi dry Roth, Karlsruhe, 
Incubator Function Line Heraeus, Hanau 
Cryostat CM 1950 Leica, Wetzlar 
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3.1.9.  Animals  
An established mouse model for scleroderma, originally described by Yamamoto et al., (1999) 
was used for evaluating the anti-fibrogenic effect of diphenyleneiodonium (DPI) in vivo. Six- to 
eight-week-old female C3H/HeJ (The Jackson Laboratory, USA) mice were randomly divided 
into 4 groups (7 mice per group) as follows: BLM (10 µg), DPI (40 µg), BLM plus DPI and 
NaCl (negative control). Mice received daily subcutaneous injections of bleomycin (10 µg) or 
filter-sterilized 0.9 % saline into the dorsal shaved skin. DPI (2 mg/kg) was daily administered 
by intraperitoneal (IP) injections. After 4 weeks of injection, mice were sacrificed and skin 
biopsies were collected under sterile conditions and processed for RNA extraction followed by 
real-time PCR for measurement of collagen type I and routine H&E histochemistry. Mice were 
housed under controlled conditions with free access to food (standard rat chow diet) and water. 
All experimental animal procedures were performed under approval of the local veterinary 
authorities (District Government and District Veterinary Office, university of Münster, 
Germany) (8.87-51.04.20.09.384). 
3.1.10.  Software and computer programmes 
3.1.10.1.  Online Tools and databases  
 BLAST (Basic Local Alignment Search Tool): http://www.ncbi.nlm.nih.gov/BLAST 
 ClustalW (multiple sequence alignments): http://www.ebi.ac.uk/Tools/clustalw/index.html 
 Ensembl Genome Browser: http://www.ensembl.org/index.html 
 Genomatix (MatInspector, etc.): http://www.genomatix.de/ 
 NCBI (National Center of Biotechnology Information): http://www.ncbi.nlm.nih.gov/ 
 AliBaba 2.1: http://www.gene-regulation.com/pub/programs/alibaba2/index.html 
 PROMO: http://alggen.lsi.upc.es/cgibin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3 
 
3.1.10.2.  Software 
Name                                                           Company 
Zen2011, Carl Zeiss software                 Carl Zeiss, Göttingen   
Endnote X4                                            Thomson Reuters, Carlsbad, USA 
Origin                                                     Additive GmbH, Friedrichsdorf 
Adobe Illustrator C5                              Adobe Systems GmbH, München 
Adobe Photoshop C6                             Adobe Systems GmbH, München 
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3.1.11.  Cells, cell lines and cell culture reagents 
Table 14: List of human and mouse cell used in this study 
Name  Species  Description  Source  
nHDF Human Normal human dermal fibroblast  Tebu-bio, 
aHDF Human Adult human dermal fibroblast Tebu-bio, 
SScHDF Human HDF from SSc patients were received from SSc patients, 
WWU Münster (UKM) Clinic  
HUVEC Human Human Umbilical Vein Endothelial Cells Provided by Prof. H. Schnittler, 
were isolated from Fresh human 
umbilical cords, WWU Münster 
(UKM) Clinic 
MNC Human Mononuclear Cells Promocell,  
NHK Human Normal human keratinocytes Promocell, 
CaCo2 Human human colon epithelial cancer cell line Promocell, 
Nox4-/- Mouse Fibrosarcoma cells  Supplied by Prof. K. Schröder 
 
3.2.  Methods 
3.2.1.  Cell biological methods  
3.2.1.1.  Cultivation of cells 
Primary cells and cell lines used in this study are listed in Table 14. The human dermal 
fibroblasts (HDFs) were cultured and maintained at 37 °C in a humidified 5% CO2 atmosphere in 
RPMI 1640 medium supplemented with 10 % fetal bovine serum, 1 % penicillin/streptomycin 
and 1% L-glutamine. The fibroblasts were to a maximal passage 6-7. After reaching 80 % 
confluencye, cells were washed once with PBS (without Ca2+ and Mg2+) and detached from 
surface by incubation with trypsin/EDTA solution at 37 °C. After 5 min incubation, 
trypsinization process was inactivated by adding serum containing culture medium. Cell number 
and viability were determined using Trypan blue Solution (1:1) using the Neubauer chamber 
hemocytometer. 
3.2.1.2.  Freezing of cells and storage  
Cells were gently detached from culture tissue flask using trypsin/EDTA solution. Subsequently, 
they were pelleted by centrifugation at 1200 rpm for 5 min and resuspended in 1.5 ml RPMI 16 
medium containing 20 % (v/v) FCS, 10 % (v/v) dimethyl sulfoxide (DMSO). The cell 
suspension was transferred to 1.5 ml cryo-vials which were stored at -80 °C overnight and then 
transferred to liquid nitrogen at 180 °C for long term storage.  
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Frozen cryo-vials were quickly thawed at 37 °C in a water bath. The cells were pelleted at 1200 
rpm for 5 min and subsequently resuspended in fresh RPMI 1640 medium supplemented with 10 
% FCS, 1 % Penicillin/Streptomycin und 1 % L-glutamine at a density of 1 x 106 cells/cm2. 
Culture medium was replaced the following day to remove residual DMSO. 
3.2.1.3.  Generation of Nox4-/--deficient murine fibroblasts 
 Nox4-/- mice were generated by targeted deletion of the translation initiation site and of exons 1 
and 2 of the Nox4 gene (Schröder, Zhang et al. 2012) and backcrossed into C57Bl/6J for more 
than 10 generations. To induce fibrosarcomas the chemical carcinogen methylchoanthrene was 
injected subcutaneously into the right flank of the mice. In case tumors reached a diameter of 1.5 
cm or 150 days after methylchoanthrene injection mice were sacrificed and if present the tumor 
tissue was used for cell isolation. Fibrosarcoma cells were isolated using the tumor dissociation 
kit for mouse and the gentle MACS Dissociator (Miltenyi Biotec), following the manufactures 
instructions. Shortly, tumor tissue was homogenized enzymatically, erythrocytes were lysed and 
eventually cells were cultured in Dulbecco’s Modified Eagle’s Medium+ glutaMAX (Gibco) 
supplemented with 5 % FCS , 1 % penicillin (50 U/ml) and streptomycin (50 µg/ml) in a 
humidified atmosphere of 5 % CO2 at 37 °C. Erythrocyte depletion buffer consisted of 155 mM 
NH4Cl, 10 nM NaHCO3 and 100 nM EDTA in double distilled water, pH=7.4. All animal 
experiments were approved by the local governmental authorities (F28/46) and were performed 
in accordance with the animal protection guidelines.  
3.2.1.4.  Generation of skin samples and HDFs from patients with SSc 
 Samples from lesional skin were received from SSc patients undergoing routine diagnostic 
biopsies. Samples from n=3 patients (age: 33-67; 2 females, 1 male; biopsy sites: finger, neck, 
abdomen; ANA phenotype: 2 anti-SCL70, 1 anti-CENP-B) were immediately frozen in liquid 
nitrogen and further processed for total RNA preparation as indicated below. HDFs from lesional 
skin of n=3 SSc patients were established and maintained as previously reported (Stegemann et 
al., 2013). The patient characteristics were: age: 50-72; 2 females, 1 male; biopsy site: dorsal 
lower arm; ANA phenotype: 1 anti-SCL70, 1 anti-CENP-B, 1 ANA-negative. All patients 
fulfilled the ACR criteria for diagnosis of SSc. Studies were approved by the Local Ethical 
Committee of the University of Münster, Germany (2013-020-f-S).  
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3.2.2.  Molecular biological methods  
3.2.2.1.  RNA isolation 
Total cellular RNA extraction from individual cell types was carried out with the RNeasy mini 
kit (Qiagen, Hilden, Germany), according to the manufacturer’s instructions. Briefly, medium 
was aspirated; adherent cells were washed once with PBS and scraped in lysis buffer. After 
centrifugation for 2 min at 13.000 rpm the homogenized cell lysate was mixed with 400 µl 70 % 
ethanol and centrifuged for 2 min at 13.000 rpm 3 times. After several washing steps through 
RNeasy spin column, total RNA from the membrane was eluted with high purity by using 40 µl 
of RNase free H2O and centrifuge for 1 min at 8600 rpm. To eliminate potential DNA 
contamination, RNA (1 μg) was mixed with H2O and 10 μl of DNAse (Promega (1 U/μl) to a 
final volume of 100 µl and incubated for 90 min at 37 °C and 10 min at 65 °C. The concentration 
of the RNA was determined by the optical density of the sample at wavelengths of 260 and 280 
nm using spectrophotometer. An OD260 of 1 corresponded to a RNA concentration of 40 µg/ml. 
The purity of the RNA solution was evaluated measuring an aqueous solution of RNA via UV 
absorption at 260 nm and 280 nm. The ratio of OD260/280 ratio should be between 1.8 to 2.0. 
The RNA was stored at -20 °C until further use for the cDNA synthesis and subsequent RT-PCR. 
Before RNA isolation from murine and human samples, frozen tissues were homogenized in 
tubes containing homogenization beads and placed in homogenizer (Thermo Scientific, Sweden) 
for 1 min at 2000 rpm. Total RNA was isolated using Trizol reagent according to a modified acid 
guanidium thiocyanate-phenol-chloroform extraction method (Chomczynski & Sacchi 1987). 
Shortly, 1 ml of Trizol reagent was added to 50-100 mg homogenized tissue and incubated for 5 
min at room temperature (RT) to permit the complete dissociation of nucleoprotein complexes. 
Then, 200 µl of chloroform was added per 1 ml of TRIZOL Reagent. The tubes were shaken 
vigorously for 15 seconds then incubated at room temperature for 2 to 3 min. Samples were 
centrifuged at 13,000 rpm for 15 min at 4 °C. After centrifugation, the mixture was separated 
into a lower phase, phenol chloroform phase, an interphase, and an upper aqueous phase. The 
aqueous phase was transferred to a fresh tube and 500 µl isopropyl alcohol was added to allow 
precipitation of RNA. Samples were incubated at 4 °C overnight and were then centrifuged at 
13,000 rpm for 10 min at 4 °C. After centrifugation, the pellets were washed twice with 70% 
cold ethanol and were centrifuged again at 13,000 rpm for 5 min at 4 °C. The supernatant was 
removed and the RNA pellets were kept 5 min at room temperature to air dry. Finally, RNA 
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pellets were dissolved in 20 µl RNase-free water at 60 °C for 5-10 min to help dissolving and 
subsequently and stored at -20 °C until use.  
3.2.2.2.  cDNA synthesis and reverse transcription 
RNA was reverse transcribed into first-strand cDNA using the Revert AidTM cDNA Synthesis 
Kit (Fermentas Life Sciences). 1 µg of template RNA was first incubated with 1 µl of oligo 
(dT)18 primer (0.5 µg/µl) and the volume was made up to 12 µl with RNase free water. The 
reaction mixture was gently vortexed then incubated for 5 min at 65 °C in the thermoblock. 
Immediately after incubation, the tube was briefly centrifuged and placed on ice. The following 
reaction mixture was added in the indicated order: (4.2 µl of 5 x reaction buffer, 2 µl of 10 mM 
dNTP mix, 1 µl of RevertAid reverse transcriptase and 1 µl RiboLock™ Ribonuclease Inhibitor). 
The total volume was made up to 20 µl with RNase free water. The tubes were mixed gently, 
briefly centrifuged and incubated at 42 °C for 60 mins in a thermal cycler. The reaction was then 
terminated by heating at 70 °C for 10 mins and the resulting cDNA was used for RT-PCR 
analysis or stored at -20 °C until further use. 
3.2.2.3.  Polymerase chain reaction (PCR) 
a) Semi-quantitative RT-PCR 
Endpoint polymerase chain reaction (PCR) was used to amplify specific DNA‐fragments. For all 
PCR reactions a master mix was prepared contained the following components : 1-3 µl of cDNA 
products; 5 μl 5X PCR buffer, 0.5 μl of 10 mM dNTPs, 3 μL of each primer (40 pmol); 0.125 µl 
of Promega GoTaq polymerase (5 U/µl) and RNA free water up to 25 µl. All the primer 
sequences used in this study are listed in Table 8-9. Our oligonucleotide primers were designed 
using Primer Express (Perkin- Elmer Life Sciences, Courtaboeuf, France) and generated by 
Biozyme or those cited in earlier studies. The specificity of the sequences was verified using the 
Blast Nucleotide software available at the National Center for Biotechnology Information.  
The number of cycles and the program condition were optimized for each gene separately to 
ensure that no artefacts of the PCR reaction were generated. Reactions were performed in a 
Thermocycler for generally 33-35 cycles using the following standard amplification Program:  
Initial denaturation   94 °C, 5 min 
Denaturation        94 °C, 1 min 
Annealing          Tm-4 °C, 1 min x °C,  Repeated 33-35 times 
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Elongation         72 °C, 1 min/kb DNA 
Termination        72 °C, 10 min  
Cooling to 4 °C  
The optimal annealing temperature (OAT) of the primers was calculated for each individual 
primer and is averaged for the primer pair according to the following formula described in 
(Sambrook et al. 1999):  
OAT = Tm – 4 ºC  
Where Tm is the melting temperature of the DNA, which is calculated from the G/C content, and 
is calculated by:  
Tm = 4(G+C) + 2(T+A) ºC 
We usually performed a negative control containing RNA instead of cDNA to rule out genomic 
DNA contamination. After cycling the reaction was diluted 1:5 by adding 80 µl nucleases free 
water to the 20 µl reaction mixture product. Samples were stored at -20 °C until further use. 
b)  Quantitative real-time RT-PCR 
Real-time PCR analysis was performed with SYBR Green ROX PCR Master Mix Reagent 
(Thermo Fisher Scientific). The real-time PCR mixture was prepared according to the 
manufacturer’s protocol. Briefly, reaction mix was made by mixing 10 µl of SYBR green, 4.6 µl 
of water, 0.4 µl of the primer mix (10 µM working solution). Each well of 96 well plates should 
have 5 µl of cDNA at the appropriate dilution and 20 µl of the RT-PCR reaction mix. The final 
volume per well should be 25 µl. Reactions were carried out for 40 cycles (95 °C for 15 s and 60 
°C for 60 s) in duplicates using an ABI-prism 7300 sequence detector (Applied Biosystems). 
Relative expression of the gene of interest(the n-fold expression) is carried out or calculated 
according to The delta Ct (2-ΔΔCt) method (Livak and Schmittgen, 2001) where Delta Ct (ΔCt) 
values were calculated by subtracting the mean Ct of the housekeeping gene from the mean Ct of 
the gene of interest. β-actin was used as an internal standard (housekeeping gene) and triplicate 
measurements were performed for each sample. 
3.2.2.4.  DNA gel electrophoresis 
Amplified PCR products were separated on a 1.5% agarose gel (1X TBE buffer) containing 0.5 
mg/ml Red safe together with a DNA marker for the appropriate fragment length. The 
electrophoresis was performed for around 1 h with 5 V/cm and DNA bands were visualized by 
UV light. Gel Images were captured by chemiluminescence imager (FUSION-FX7 Advance™). 
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The size of DNA fragments was determined by comparison with a DNA marker for the 
appropriate fragment length 
3.2.2.5.  siRNA transfection and gene knock-down 
HDFs were transfected with small interference RNA (siRNA) against Nox4 and SMAD3 or non-
targeting ON-TARGET plus control siRNA#2 according the manufacturer’s protocols. 
Sequences of siRNAs used in this study have been described before in Table 10. Briefly, 
250,000 cells were seeded in a 3.5 cm cell culture plate with RPMI1640 medium containing 
serum without antibiotic for 24 h, HDFs were cultured to 60-70 % confluence. For each plate, 10 
µL siRNA (siRNA was diluted in sterile nucleases free water to a final concentration of 25 nM) 
and 4 µl transfection reagent in 200 µl transfection medium (serum and antibiotic free RPMI 
1640 medium) were prepared and incubated for 5 min at RT. Both preparations were mixed and 
incubated for 20 min at RT. Transfection complex was added drop wise to cell medium. After 48 
hrs of incubation, transfection medium was removed and a new fresh RPMI 1640 medium 
containing 0 % serum and antibiotic added for further 24 hrs deprivation prior to treatments. 
Subsequently, cells were stimulated with or without TGF-β1 as indicated and harvested for RNA 
extraction. Specific silencing of targeted genes was confirmed by RT-PCR analysis. 
3.2.3.  Biochemical methods 
3.2.3.1.  Preparation of cell extract 
3.2.3.1.1.  Preparation of cell lysate using hot lysis method  
Prior to lysis, cells were grown to 70-80 % confluence and treated with stimulants or inhibitors 
according to the experimental design. Cells were washed with cold PBS and harvested by 
scraping in hot 6 x SDS sample buffer using a rubber policeman. This was followed by 
sonication for 2 x 5 sec and incubation at 95 °C for 5 min. Equal amounts of protein (30 µg/lane) 
were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis. 
3.2.3.1.2.  Preparation of cell lysates using immunoprecipitation buffer (IP). 
After cell treatments, they were washed with ice cold PBS and harvested by scraping in PBS 
followed by centrifugation at maximum speed for 5 mins at 4 °C. Subsequently, cell pellets were 
resuspended in IP buffer and were incubated for 60 min on ice. After incubation in ice, samples 
were sonicated for 2 x 5 sec and centrifuged at 14.000 rpm for 10 mins at 4 °C. The supernatant 
38 | 
Material and Methods 
 
was transferred into a fresh microcentrifuge tube and the pellet was discarded. The protein 
concentrations of the lysates were determined using Bradford method as described later in 
(3.2.3.2). 30-50 µg of protein sample was mixed with 6x SDS sample buffer containingβ-
mercaptoethanol and then heated at 95 °C for 5 min. The samples were stored at -20 °C until 
further use.  
 
3.2.3.2.  Protein determination 
Total protein concentration was measured using Bradford methods (Bradford 1976). Protein 
sample (5 µl) was dissolved in 100 µl of diluted Bradford reagents and then incubated for 5 min 
at room temperature. As a blank, 5 µl of the IP buffer were dissolved in 100 µl of diluted 
Bradford reagents the samples were mixed by pipetting gently. After incubation, the samples 
were transferred to cuvettes and absorbance was measured using spectrophotometer at 595 nm.  
3.2.3.3.  SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Protein samples were separated on vertical, discontinuous SDS-polyacrylamide gel as described 
previously (Sambrook, 1990). According to the molecular weight of the protein of interest, the 
acrylamide concentration was adjusted to 10 % or 12 % at constant voltage of approx. 90 V in 
the stacking gel (Table 16) and at 120-130 V in the separating Gel (Table 15). The molecular 
weight of All proteins examined in this study ranges between 70:19 kDa (Nox4: 67 kDa, 
P22phox:19 kDa, Poldip2: 42 kDa, β-actin: 43 kDa and α-tubulin: 55 kDa). The run of the gel was 
controlled by separation of pre-stained molecular weight marker as a size reference. 
 
Table 15: Components of separating gel  
 
Seperating gel components Volume (5 ml)  
10%  
H2O                         
30 % Acrylamide-Mix 
1.5 M Tris (pH 8.8) 
10 % SDS 
10 % Ammonium persulfate 
TEMED 
 
1.9 
1.7 
1.3 
0.05 
0.05 
0.002 
12%  
H2O                         
30 % Acrylamide-Mix 
 
1.6 
2.0 
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1.5 M Tris (pH 8.8) 
10 % SDS 
10 % Ammonium persulfate 
TEMED 
1.3 
0.05 
0.05 
0.002 
 
 
Table 16: Components of stacking gel  
Stacking gel components Volume (2ml)  
5%  
H2O                         
30% Acrylamide-Mix 
1.5 M Tris (pH 8.8) 
10% SDS 
10% Ammonium persulfate 
TEMED 
 
1.4 
0.33 
0.25 
0.02 
0.02 
0.002 
 
3.2.3.4.  Western immunoblotting  
After separation on SDS gels, proteins were blotted onto polyvinylidene difluoride membranes 
(PVDF) (Immobilon-P, 0.45 µm, Millipore) according to Towbin Methods (Towbin et al., 1979). 
PVDF membranes were activated in methanol for 15 sec and equilibrated in blotting buffer for 
15 min at room temperature. Gel and membrane were placed with three layers of Whatman paper 
in the electroblotting chamber. The semi‐dry electroblotting was performed at a constant current 
of approx. 200 mA for 1 hr. After proteins transfer, the PVDF membrane was washed using 2 x 
TBST buffer and then blocked with 10 % BSA/TBST at 4 °C. After blocking, the membrane was 
incubated with the primary antibody diluted in the same buffer overnight at 4 °C at the 
appropriate concentration as described earlier in Table 11. The next day, the PVDF membrane 
was washed with 2 x TBST buffer three times for 5 mins and subsequently incubated with the 
appropriate secondary antibody conjugated to Horse Radish Peroxidase (HRP) enzyme for 30 
min. The membrane was washed with 2 x TBST buffer three times for 5 min. Protein bands were 
visualized on the membrane using enhanced chemiluminescence (ECL). The ECLplus reaction 
mixture (Enhanced Luminol Reagent and Oxidizing Reagent) was prepared according to the 
manufacturer`s instruction (Roti-Lumin-Kit) and incubated with nitrocellulose membrane for 
1  min, and signals were detected with the Amersham Hyperfilm ECL (GE Healthcare). The film 
was placed in developer solution (G153, AGFA) until black bands appeared, washed in 1 % 
acetic acid und finally placed in fixer solution (G35A,AGFA) for a couple of mins. After 
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fixation, the film was washed in water and dried. Densitometric analysis was performed using 
the Image J software. To assure equal loading, membranes were stripped for 10-15 min at room 
temperature, and reprobed with an antibody against β-actin (Santa Cruz) or α-tubulin.  
 
3.2.4.  Immunological methods  
3.2.4.1.  ELISA 
A commercially available Enzyme-linked immunosorbent assay (ELISA kit, TaKaRa) was used 
to measure the procollagen I C-peptide (PICP) secretion. Briefly, 250,000 cells per well were 
seeded into 12-well tissue culture plates. HDFs were deprived of FCS for two days and 
subsequently stimulated with TGF-β1 alone or in combination with DPI. Cell culture 
supernatants were harvested after 48 hrs, and centrifuged at 2500 rpm for 5 min to remove pellet 
debris. The resulting supernatant was transferred into fresh microcentrifuge tubes and samples 
were centrifuged and frozen at -80 °C until use. At the time of measurement, samples were 
thawed on ice. The assay was performed according to the manufacturer’s instructions, in 96 well 
plates precoated with Procollagen Type I C-Peptide (PIP) antibody. First, 100 μl of lyophilized 
horseradish peroxidase (POD) conjugated murine monoclonal antibody solution were added to 
each well, and subsequently add 20 μl sample or standard of known concentrations. The samples 
were carefully mixed and then incubated for 3 hrs at 37 ℃ followed by washing 4 times with ca. 
400 μl of PBS. Samples were then incubated with 100 μl of substrate solution for 15 mins at 
room temperature in the dark, after which, 100 μl of stop solution (1 N H2SO4) was added to 
terminate the reaction. The optical density was measured with a microplate reader at 450 nm. 
The concentration of procollagen I C-peptide in the supernatants were determined against a 
standard curve from the standard procollagen I C-peptide samples used on the same 96 well plate 
3.2.5.  Cytotoxicity assays  
Cytotoxicity was evaluated using both crystal violet staining method and XTT test after 
treatment with different Nox inhibitors.  
3.2.5.1.  Crystal violet assay 
Crystal violet (CV), a triphenylmethane dye (4-[(4-dimethylaminophenyl)-phenyl-methyl]-N,N-
dimethyl-aniline) and was used to determine cell viability after treatment with DPI or VAS2870 
41 | 
Material and Methods 
 
Nox inhibitor. HDFs were seeded into 12-well culture plates at a density of 7,000 cells per well 
and cultivated for 24 hrs at 37 °C. After incubation, DPI or VAS2870 (dissolved in DMSO) was 
added at various concentrations as indicated and incubated 16 hrs at 37 °C. after this period, the 
medium was removed and the cells were washed with 1 x PBS and then stained with 0.1 % 
crystal violet solution in methanol with gentle shaking for 20 min at room temperature. Stained 
cells were carefully washed three times with 1 x PBS water until a clear background was visible 
and were left to dry overnight. CV was dissolved using lysis buffer (10 % methanol and 10 % 
acetic acid) for 15 min at room temperature with gentle shaking. Absorbance was measured 
spectrophotometrically at 590 nm by an automated microplate reader ELx808 (BioTek, Bad 
Friedrichshall, Germany). The experiments were repeated three times. 
3.2.5.2.  XTT test 
XTT is 2, 3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilid. XTT kit was 
provided from Roche Diagnostics (Karlsruhe) was used to determine cell proliferation after 
treatment with the Nox inhibitor. Briefly, 10,000 cells per well were seeded into 96-well tissue 
culture plates and incubated up to 24 hrs. After incubation, DPI or VAS2870 (dissolved in 
DMSO) was added at various concentrations as indicated and incubated 16 hrs at 37 °C. 50 µl 
XTT-labelling reagent and 1 µl electron coupling reagent were mixed and 50 µl from that 
mixture was added to each well containing 100 µl culture media (final concentration: 0,3 mg/ml) 
and incubated for 4-24 hrs at 37 °C. Absorbances were recorded at 490 nm by an automatic 
microplate reader ELx808 (BioTek, Bad Friedrichshall, Germany). Similar results were found in 
three independent experiments with four replicates for each dose. 
3.2.6.  Confocal immunofluorescences microscopy 
HDFs were seeded on gelatin-coated glass coverslips in RPMI 1640 medium, after setting the 
experimental condition, cells were fixed with methanol at -20 °C or with 4% paraformaldehyde 
for 15 min, then washed for 5 min with PBS and blocked with 5 % goat serum. After blocking, 
cells were incubated for 1 hr at room temperature or overnight at 4 °C with the primary 
antibodies. Primary antibodies used in this study are listed in Table 11. In separate colocalization 
experiments, HDFs were loaded with MitoTracker Deep Red (MTR) (250 nmol/l, 30 min at 37 
°C) (Invitrogen) followed by incubation with Nox4 antibody. After another washing step, the 
secondary corresponding fluor 488 or Alexa fluor 568 antibodies were applied (1:1000, 
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Invitrogen) for 1 hr at room temperature (Table 12). Nuclei were stained with 4', 6-diamidino-2-
phenylindole (DAPI) (Fluka). Cells were mounted in fluorescence mounting medium (Roth) and 
observed under oil immersion 40 X or 63 X objective on an inverted LSM 780 confocal laser-
scanning microscope (Carl Zeiss). Comparative IF images were acquired under the same 
microscopic setting. Results represent images from at least three independent experiments.  
3.2.7.  Assessment of dermal thickness.  
4 µm sections of paraffin-embedded skin from mice treated with NaCl, bleomycin, DPI, or 
bleomycin plus DPI were de-paraffinized, rehydrated and then stained with hematoxylin and 
eosin (H&E) according to the standard protocols of our laboratory. Dermal thickness was 
determined using a Zeiss Axiophot microscope. Three measurements were performed for each 
microscopic field, and 5 different fields were analysed for each mouse (n= 3). Densitometric 
analysis was performed using ImageJ software. 
3.2.8.  Determination of collagen protein content ex vivo. 
Mouse skin samples were weighed and incubated in 0.5M acetic acid in the presence of protease 
inhibitor cocktail (Roche Diagnostics). One milligram of pepsin (Sigma) per 500 µl 0.5M acetic 
acid was added to each sample, followed by incubation for 24 hrs at 4°C. After centrifugation, 
supernatants were precipitated with methanol/chloroform, after which 2X Laemmli sample 
buffer was added to dissolve the protein pellets. After normalization for wet weight, samples 
were subjected to SDS-PAGE and stained with 0.5 % Coomassie brilliant blue (Bio-Rad). 
3.2.9.  In silico promoter analysis  
Coding promoter sequences of the human Nox4 gene (~ 4 kb upstream) were obtained from the 
ENSEMBL genomic database. The AliBaba 2.1/TRANSFAC 8.3 web based tool was used to 
predict the transcription factor binding sites in the sets of sequences. The stringency level was set 
to a value of 0.9, and the human promoter set of the Eukaryotic Promoter Database was chosen 
as third order background model. 
3.2.10.  Measurement of NADPH oxidase activity assay 
HDFs (106 cells per treatment) were seeded out in 10 cm diameter culture dishes. After 
deprivation from FCS for 24 hrs Cells were treated in the presence or absence of DPI, 
administered 1 h min before the stimulation with TGF-β1 for further 24 hrs. Cells were washed 
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with ice cold PBS and harvested using scraping out of petri dish then centrifuged. Cell Pellets 
were homogenized with 100 strokes using a Dounce homogenizer on ice in lysis buffer 
containing 20 mM KH2PO4 (pH 7.0), 1 mM EGTA and protease inhibitor. Cell homogenate 
subjected to differential centrifugation to isolate membrane fraction. A total of 100 µl of 
membrane fraction (50 µg total protein) was immediately added to 900 µl of 50 mM phosphate 
buffer (pH 7) containing 1 mM EGTA, 150 mM sucrose, 500 µM lucigenin as an electron 
acceptor, and 100 µM NADH as an electron donor. Photon emission expressed as relative light 
units was measured every 25 s for 30 min in a microplate luminometer Centro LB960 (Berthold 
Technologies). There was no measurable activity in the absence of NADH. A buffer blank was 
subtracted from each reading before calculation of the data. The protocol used was optimised 
from (Abid et al., 2007). 
3.2.11.  Statistical analysis  
All experiments were performed at least three times, unless stated otherwise. Results were 
expressed as means ± SEM and deviations from normality were assessed by the Shapiro-Wilk 
test. Statistical significance in the differences between two mean values was determined by the 
student’s t-test. Differences were considered as signiﬁcant when p<0.05. 
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4.  Results 
4.1.  Detection of Nox isoforms and adaptor proteins in HDFs 
4.1.1.  Expression of Nox4 isoform and its adaptor proteins in normal HDFs  
In a first set of experiments we performed a detailed expression analysis of the Nox4 isoform and 
its adaptor proteins in HDFs derived from both normal neonatal foreskin (nHDFs) and adult skin 
(aHDFs) (n=3 donors, each) by semi-quantitative RT-PCR analysis. Interestingly, HDFs derived 
from neonatal foreskin and adult HDFs constitutively express mRNA levels for Nox4. Fig. 8A, 
shows a representative analysis for one donor). Moreover, both cell types expressed steady-state 
levels of the Nox4 adapter proteins p22phox and Poldip2, suggesting a functional Nox4 complex. 
State of the art negative controls of the utilized cDNA samples from nHDFs (RNA without RT) 
were negative. State of the art positive controls (human umbilical vein endothelial cells 
(HUVEC) were positive for Nox4 and its adapter proteins. These findings on HDF derived from 
neonatal foreskin and adult skin were confirmed in cells from two other donors. 
Next, we verified that all components of a functional Nox4 complex are also present at protein 
level in nHDFs and aHDFs. Protein samples were subjected to SDS-PAGE followed by Western 
blot analysis. β-actin was used as internal control for equal protein loading. We detected Nox4, 
p22phox and Poldip2 by Western immunoblotting in nHDFs (Fig. 8B) at the expected molecular 
weights. State of the art positive control HUVEC was used. 
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Figure 8. Expression analysis of Nox4 and its adaptors in HDFs. (A) Detection of Nox4 as well 
as its adaptors p22phox and Poldip2 in nHDFs and aHDFs by endpoint RT-PCR analysis. State of the art 
positive and negative controls consisted of cDNA from HUVEC and HDF templates without RT. (B) 
Detection of Nox4, p22phox and Poldip2 protein in nHDFs and aHDFs by Western blotting. Reprobing the 
membrane with an anti-β-actin antibody was used as control for equal protein loading. Data are 
representative images of n=3 donors of nHDFs with similar results. MW, molecular weight; bp, base 
pairs. 
4.1.2.  Expression of Nox4 isoform and its adaptor proteins in affected skin and HDFs from 
SSc patients 
In another set of experiments we explored the expression pattern of the complete Nox4 complex 
in HDFs from SSc patients. The endpoint RT-PCR analysis demonstrated that diseased HDF 
constitutively expressed mRNA transcripts for Nox4 as well as its associated adaptor proteins 
p22phox and Poldip2 (n=3; Fig. 9A and B show qualitative PCR analysis of 3 healthy donors and 
3 SSc patients). Interestingly, quantitative RT-PCR analysis revealed that Nox4 mRNA 
expression was similar between normal adult and SSc HDF (Fig. 9C). Since levels of mRNA do 
not always directly correlate with protein levels, which can arise through differences in 
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mRNA/protein stability or post‐transcriptional/translational modifications (Yoshiko, Hirao et al. 
2002), we evaluated Nox4 expression by Western immunoblotting analysis of total cell lysates 
from both adult HDFs and SSc HDFs. 30 µg of protein was loaded per well and β-actin was used 
as a loading control (Fig. 9D). The Nox4 antibody detected a protein band at 67 kDa in both cell 
types; however, the protein band was more strongly abundant in at least 2 donors fibroblasts 
from SSc patients than in adult HDFs. In summary, these findings confirmed the presence of a 
complete Nox4 complex in SSc skin and HDFs from patients with SSc. 
 
Figure 9. Expression of the Nox4 and its adaptors was preserved in affected skin as well as 
in HDFs of patients with SSc. (A) Detection of the Nox4 and its adaptors p22phox and Poldip2 in SSc 
skin as shown by endpoint RT-PCR. State of the art positive and negative controls consisted of cDNA 
from HUVEC and HDFs templates without RT. Images were representative for skin samples (n=3) with 
identical results. (B) Detection of Nox4, p22phox and Poldip2 in HDFs derived from SSc patients (n=3) by 
endpoint RT-PCR. State of the art positive and negative controls consisted of cDNA from HUVEC and 
HDF templates without RT. (C) Normal adult HDF (n=3) and SSc HDF (n=3) do not vary in Nox4, 
p22phox and Poldip2 mRNA expression as shown by real-time RT-PCR. Depicted are Ct-values 
normalized to GAPDH. (D) Nox4 protein expression in adult HDF (n=3) and SSc HDF (n=3) as shown 
by Western immunoblotting. 
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4.1.3.   Expression of other Nox isoforms, cytosolic subunits and adaptor proteins in normal 
nHDFs  
To get first insights into the mRNA expression of other Nox isoforms and their adaptor proteins 
in healthy HDFs, we performed semi-quantitative RT-PCR analysis of HDFs derived from both 
nHDFs and aHDFs (n=3 donors, each). As shown in Fig. 10, these cells constitutively express 
steady-state levels of the small GTPases Rac1 and Rac2. Moreover, nHDFs and aHDFs express 
low level of Duox1 and Nox5. In contrast, Nox1, Nox2/gp91phox (the prototypic phagocytic Nox 
isoform), Duox2, p40phox, p47phox and p67phox were not detectable by semi quantitative RT-PCR. 
These findings on HDFs derived from neonatal foreskin were confirmed in cells from two other 
donors. Similarly, none of the other NOX components, i.e Nox2 or Nox3, p40phox, p47phox and 
p67phox were detectable by semi-quantitative RT-PCR in aHDFs (Appendix Fig. 1). State-of the 
art negative controls of the utilized cDNA samples from HDFs (RNA without RT) were 
negative. State-of the art positive controls (human peripheral blood monocytes, CaCo2 cells) 
were positive for Nox1 and Nox2/gp91phox. We did not examine Nox3 since Nox3 is selectively 
expressed in the inner ear (Banfi, Malgrange et al. 2004). 
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Figure 10. Expression analysis of additional Nox isoforms, adaptor proteins as well as Rac1 
and Rac2 in normal nHDFs by endpoint RT-PCR analysis. Expression analysis of additional 
Nox isoforms, adaptor proteins as well as Rac1 and Rac2 in normal nHDFs by endpoint RT-PCR 
analysis. State of the art positive controls consisted of cDNA from HUVEC, normal human keratinocytes 
(NHKs), human peripheral blood monocytes (MNC) and the human colon carcinoma cell line CaCo2. 
Negative controls consisted of HDF templates without RT. Depicted are representative images from RT-
PCR analyses of n=3 donors. 
 
4.1.4.  Expression of additional Nox isoform and adaptor proteins in HDFs from SSc 
patients 
In order to get qualitative information about mRNA expression profiling of additional Nox 
family members in SSc HDFs (n=3 donors), their expression was characterized in HDFs from 
SSc patients. Notably, endpoint RT-PCR analysis revealed no presence of other Nox isoforms 
such as Nox1, Nox2 including its adapters p40phox, p47phox, p67phox or Duox1 using state of the art 
positive and negative controls (representatively shown in Fig. 11 for one donor). However, in 
accordance with the expression pattern in nHDFs and aHDFs, SSc HDFs expressed transcripts 
for Rac1, Rac2 and low level of Nox5. 
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Figure 11. Expression analysis of additional Nox isoforms, adaptor proteins as well as Rac 
1 and Rac2 in HDFs from patients with SSc by endpoint RT-PCR. Positive controls consisted 
of HUVEC, normal human keratinocytes (NHKs), human peripheral blood monocytes (MNCs) and the 
human colon carcinoma cell line CaCo2. Negative controls consisted of HDF templates without RT. 
Depicted are representative images from RT-PCR analyses of n=3 donors. 
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images were taken at a 63x magnification of 3 independent experiments. Scale bar is 20 µm. (B) 
Detection of Nox4 immunoreactivity in SSc HDFs by double immunofluorescence analysis and confocal 
laser-scanning microscopy. Nox4 colocalized with the ER marker PDI. Scale bar: 20 µm. Images are 
representative for n=3 donors with identical results 
 
Since several studies reported various subcellular localization of Nox4 isoform within different 
organelles in different cell types, we further investigated the localization of Nox4 within 
mitochondria, lysosome and focal adhesion. In separate experiments, HDFs were stained with 
antibodies directed against either vinculin, a focal adhesion protein or against LAMP2, a marker 
of lysosomes and or with the mitochondrial marker MTR. Double-immunofluorescence staining 
did not reveal any significant co-localization of Nox4 within the mitochondria, the lysosome or 
focal adhesions (Fig. 13). Taken together, these data represent strong evidence that Nox4 
localized to the ER in HDFs.  
 
Figure 13. Nox4 did not co-localize with mitochondria, lysosomes or focal adhesion in nHDFs. Cells 
were double-stained with Nox4 antibody (green) and either the mitochondrial marker Mitotracker Red 
(red), an antibody against LAMP2 (red), or an antibody against vinculin (red). Nuclei were counterstained 
with DAPI (blue). Images are representative for 3 independent experiments with similar results. Scale bar: 
50 µm. 
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4.3.  Induction of Nox4 expression and NADPH oxidase activity by TGF-β1 in 
HDFs 
4.3.1. TGF-β1-upregulates Nox4 expression at mRNA level 
Next, we assessed the gene expression of the Nox4 complex in HDFs in the context of fibroblast 
activation by the key profibrotic cytokine TGF-β1. Cells were treated with different doses of 
TGF-β1 (0.1-10 ng/ml) for various time intervals (1- 48 hrs). Quantitative real-time PCR (qPCR) 
analysis revealed that TGF-β1 dramatically up-regulated the expression of Nox4 at the mRNA 
level in a concentration and time-dependent manner (Fig. 14A,B). Remarkable significant 
induction of Nox4 mRNA was observed at 0.1 ng/ml by (~ 10-fold) and reached maximal level 
at 10 ng/ml (~ 50-fold) (Fig. 14A). Additionally, TGF-β1 induced rapidly Nox4 gene expression 
within 4 hrs and maximal mRNA transcript level for TGF-β1 was detected after 16 h at 10 ng/ml 
followed by a decrease. However, elevated Nox4 mRNA transcript levels were observed for 48 
hrs (Fig. 14B). Indeed, treatment of aHDFs with TGF-β1 for 16 hours likewise resulted in an 
increase of Nox4 mRNA (Fig. 14C). In contrast to the upregulating effect of TGF-β1 on Nox4 
mRNA in both nHDFs and aHDFs the mRNA expression levels of the Nox4 adaptors p22phox and 
Poldip2 were not affected (Fig. 14D). Two different lot numbers of HDFs were analyzed with 
similar results. 
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Figure 14. TGF-β1-induced Nox4 mRNA expression in HDFs. (A) Dose kinetics of TGF-β1-
mediated upregulation of Nox4 mRNA expression as shown by real-time RT-PCR. Cells were treated 
with of TGF-β1 for 16 hours at indicated doses. (B) Time kinetics of TGF-β1-mediated upregulation of 
Nox4 mRNA expression as shown by real-time RT-PCR. Cells were stimulated with TGF-β1 (10 ng/ml) 
as indicated. n=4; *p<0.05; **p<0.01 vs. control. (C) TGF-β1 also induced Nox4 expression in aHDFs. 
Cells were treated with TGF-β1 (10 ng/ml) for 16 hours followed by real-time RT-PCR analysis of Nox4 
transcripts. n=4; *p<0.05 vs. control. (D) TGF-β1 did not alter expression of p22
phox and Poldip2 
expression in nHDFs. Cells were stimulated with TGF-β1 (10 ng/ml) as indicated followed by real-time 
RT-PCR analysis. n=4. 
4.3.2.  TGF-β1 upregulates Nox4 expression at protein level 
To further determine whether TGF-β1 also induced Nox4 expression at the protein level, cells 
were treated with TGF-β1 (10 ng/ml) for different time intervals and Nox4 protein expression 
was analyzed with Western immunoblotting analysis using a commercial rabbit polyclonal Nox4 
antibody. Notably, the Nox4 protein expression was also increased but showed later expression 
reached its maximum level at 16-24 hrs when compared to mRNA level, upon treatment with 
TGF-β1 (10 ng/ml) (Fig. 15A). To clarify difference between the mRNA and protein level 
expression of Nox4 in HDFs, cells were cultured in the absence of serum for 24 hrs and then 
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serum were readded and cells cultured for different time points. In order to investigate the basal 
level of Nox4 mRNA in the presence and absence of serum, we followed Nox4 mRNA levels 
after addition of serum. Nox4 mRNA amounts were significantly increased by more than 
75 %  in serum-derived nHDFs, in contrast, readdition of serum decreased the Nox4 expression 
to the basal level by 30% (Fig. 15B). Taken together, this observation needs further investigation 
to explain why mRNA expression and protein detection does not appear to be correlated.  
Consistent with our previous results, however, we confirmed the impact of TGF-β1 on Nox4 
protein expression using an immunofluorescence approach. Again, TGF-β1 showed increased 
intracytoplasmic Nox4 immunoreactivity relative to unstimulated cells (Fig. 15C). Negative 
controls incubated with secondary antibody showed no reaction  
 
Figure 15. TGF-β1 induces Nox4 protein expression in nHDFs. (A) Nox4 expression is induced 
by TGF-β1 at protein level. nHDFs were stimulated with TGF-β1 (10 ng/ml) for indicated time points 
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followed by Western immunoblotting with an antibody directed against Nox4 (2 µg/ml). (B) Detection of 
Nox4 mRNA in the presence of serum. (C) Induction of Nox4 protein by TGF-β1 as shown by 
immunofluorescence analysis (green). Cells were left untreated or stimulated with TGF-β1 (10 ng/ml) for 
16 hours. DAPI was used as nucleotracker (blue). Images are representative for 3 independent 
experiments with similar results. Scale bar: 50 µm. 
4.3.3.  TGF-β1 enhances NADPH oxidase activity 
Finally, we performed an enzymatic assay to determine if the transcriptional activation of Nox4 
by TGF-β1 leads to an increase of NADPH oxidase activity in HDFs. We specifically employed 
this assay since redox-sensitive fluoroprobes commonly used for measurement of oxidative 
stress are considered as non-specific (Kalyanaraman, Darley-Usmar et al. 2012) Therefore, cells 
were treated with TGF-β1 for 24 hrs). NADPH oxidase activity was measured using lucigenin-
enhanced chemiluminescence assay by addition of NADH as electron donors. Membrane 
fractions from nHDFs treated for 24 hours with TGF-β1 displayed markedly enhanced NADPH 
oxidase activity over control (a representative result is shown in Fig. 16. These observations 
demonstrated that Nox4 (but not the other Nox4 adaptors) was a target gene for TGF-β1 in 
HDFs. It should be noted that NADPH oxidase activity was present in both total cell 
homogenates and membrane but not in cytosolic fractions supporting the evidence that the 
cytosolic subunits are not essential for the functional activity of Nox4. 
 
Figure 16. Increase of NADPH enzyme activity by TGF-β1 Increase of NADPH enzyme activity 
by TGF-β1. Cells were stimulated with TGF-β1 (10 ng/ml) for 24 hrs. Membrane fractions were incubated 
with lucigenin and NADH as substrates. The figure is representative of 3 independent experiments with 
similar results. 
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4.4.  Functional characterization of Nox4 in TGF-β1-mediated activation of 
HDFs 
In the next set of experiments, we intended to explore the role of Nox4-dependent generation of 
reactive oxygen species in TGF-β1 signaling in cell culture. To exclude cytotoxic effects, we first 
assessed the effects of DPI and VAS2870 on cell viability in nHDFs.  
4.4.1.   Effect of the pharmacological inhibitor DPI on cell viability and metabolic activity 
in nHDFs  
Harmful effects of DPI on cell viability and metabolic activity of HDFs were analyzed by XTT 
test and crystal violet assay, respectively. HDFs were incubated with different concentrations of 
DPI for 16 hrs. Then, both XTT test and crystal violet assay were performed. The results showed 
that DPI at concentrations ranging from (1-10 µM) were neither cytotoxic nor affected cell 
viability or metabolic activity of HDFs under our experimental conditions (Fig. 17A,B). 
 
Figure 17. Effect of DPI on metabolic activity and cell viability of nHDFs as measured by crystal 
violet assay and XTT assay nHDF (105 cells /well) were seeded into 96 well plates. After serum 
starvation for 24 hrs, cells were incubated with different doses of DPI (1-10 µM). n=3; *p<0.05. 
4.4.2.   Effect of the pharmacological inhibitor VAS2870 on cell viability in nHDFs  
Then, we examined the pharmacologically validated, low-molecular-weight NADPH oxidase inhibitor, 
VAS2870, which has been shown to exert beneficial effects in the treatment of cardiovascular diseases 
and has been applied in preclinical studies in both in vitro and in vivo experiments (Altenhöfer, Kleikers 
et al. 2012). First, cells were incubated with VAS2870 concentrations ranging from 5-50 µM, and 
metabolic activity and cell viability were assessed by XTT test and crystal violet assay, respectively. The 
results showed that VAS2870 at concentrations ranging from 5-50 µM decreased viability of HDFs 
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by 40-50 % after 16 hrs of incubation (Fig. 18A, B). Therefore, concentrations higher than 10µM were 
not chosen for subsequent experiments, but concentrations ranging from (0.1- 2.5 µM). 
 
Figure 18. Effect of VAS2870 on metabolic activity and cell viability of nHDFs as measured by 
crystal violet assay and XTT test. nHDF (105 cells /well) were seeded into 96 well plates. After serum 
starvation for 24 hrs, cells were incubated with different doses of VAS2870 (1-50 µM). n=3; *p<0.05. 
4.4.3.  Pharmacological inhibition of NADPH oxidase by DPI reduces TGF-β1-mediated 
fibroblast activation 
To explore whether Nox4 activation is involved  in the cellular response of TGF-β1, we 
investigated the impact of the two established Nox inhibitors DPI, the most commonly used Nox 
inhibitor (Lambeth 2004), and VAS2870 on differentiation of fibroblasts into myofibroblasts 
which is considered a key event in fibrotic disorders (Hinz, Phan et al. 2012). First, nHDFs were 
pre-treated with DPI (10 µM) and then stimulated with TGF-β1 for 16 hrs. Then the expression 
of established myofibroblast markers such as COL(I)α1, COL(I) α2, α-SMA, and fibronectin I 
was analyzed by real-time RT-PCR. Fig. 12A shows that expression of COL(I)α1COL(I) α2, α-
SMA and fibronectin I were increased after stimulation with TGF-β1. Pretreatment of nHDFs 
with DPI significantly suppressed this stimulatory effect of TGF-β1 not only on COL(I)α1 and 
COL(I)α2 gene expression but also on the expression of α-SMA and fibronectin 1 (Fig. 19A). In 
contrast, DPI per se did not have any significant effect on the basal expression of these genes in 
nHDFs. Collectively, these data suggest that Nox4 is involved in TGF-β1-mediated 
myofibroblasts differentiation.  
To confirm these observations at the protein level, we also determined the inhibitory effect of 
DPI on TGF-β1-induced collagen type I secretion employing a procollagen type I C-terminal 
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peptide (PICP) ELISA and assessed the expression of α-SMA and fibronectin 1 by 
immunofluorescence analysis. DPI neutralized both TGF-β1-mediated secretion of collagen 
type I (Fig. 19B) and reduced TGF-β1-mediated expression of both α-SMA and fibronectin 1 
(Fig. 19C). These findings suggest that TGF-β1 via Nox4 regulates activation of HDFs and 
myofibroblast differentiation. 
 
Figure 19. Effect of DPI on TGF-β1-mediated activation of dermal fibroblasts. (A) DPI 
abrogated TGF-β1-mediated expression of collagen type I, α-SMA and fibronectin 1. nHFDs were 
preincubated with DPI (10 µM/ml) for 1 hour followed by TGF-β1 treatment for 16 hrs and real-time RT-
PCR. n=4; *p<0.05 vs. control; #p<0.05 vs. TGF-β1. (B) DPI abrogated TGF-β1-induced collagen type I 
secretion. nHDFs were treated with DPI as described followed by TGF-β1 treatment for 48 hrs and PICP 
ELISA. n=3; *p<0.05 vs. control #p<0.05. (C) DPI inhibited TGF-β1-induced α-SMA and fibronectin 1 
expression as shown by immunofluorescence. nHDFs were treated with DPI as described followed by 
TGF-β1 treatment or 16 hrs. Nuclei were stained with DAPI. Images are representative for 3 independent 
experiments with similar results. Scale bar: 50 µm. 
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4.4.4. VAS2870 does not reduce TGF-β1-mediated fibroblast activation 
Then, we also investigated the effect of VAS2870 on TGF-β1-induced fibroblast differentiation 
into myofibroblasts. As shown in Fig. 20A-C, treatment with VAS2870 resulted in a small but 
not significant decrease in TGF-β1-mediated collagen type I expression (Fig. 20A-C). Further, it 
did not effectively abolish myofibroblast marker genes expression. VAS2870 alone had no 
significant effect on the basal expression of these genes in nHDFs. Taken together, these findings 
indicate that VAS2870 could interfere with other alternative sources of ROS, such as the 
mitochondrial electron chain that have not been investigated in our study, rather than NADPH 
oxidase.  
 
Figure 20. Effect of VAS2870 on TGF-β1-mediated activation of dermal fibroblasts. VAS2870 
treatment could not effectively suppress collagen and myofibroblast marker genes expression. nHDFs 
were treated with VAS2870 (2.5 µM) for 1 h prior to stimulation with TGF-β1 (10 ng/ml) for 16 hrs. 
COL(I)α1, COL(I)α2 (A) , α-SMA (B) and fibronectin 1 (C) gene expression levels were quantified using 
real-time RT-PCR. n=3; *p<0.05 vs. control. 
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4.4.5.  Genetic knockdown of Nox4 neutralizes TGF-β1-mediated fibroblast activation 
In order to specifically confirm the role of Nox4 in both TGF-β1-incuced collagen synthesis and 
myofibroblast marker gene expression, we transfected cells with either Nox4-specific siRNA or 
control non-targeting siRNA. Transfected cells were cultured in serum-free medium for 24 hrs 
and then further stimulated with TGF-β1 for 16 hrs. First, real-time RT PCR analysis revealed 
that Nox4 mRNA expression could be significantly suppressed by ~80 % compared to scrambled 
non-targeting control siRNA, indicating high efficiency as well as specificity of the siRNA Nox4 
sequence. Second, transfection with Nox4 siRNA for 24 hours resulted in significantly reduced 
TGF-β1-inducible Nox4 mRNA levels compared to control siRNA. In accordance with our 
pharmacological studies using DPI, knock-down of Nox4 by siRNA markedly reduced the 
impact of TGF-β1 on collagen COL(I)α1, COL(I)α2, α-SMA, and fibronectin 1 gene expression 
(Fig. 21A). Interestingly, treatment of nHDFs with Nox4 siRNA further reduced basal gene 
expression of COL(I)α1, COL(I)α2,  α-SMA, and fibronectin 1. This finding was not observed 
with nHDFs treated with DPI alone. Collectively, these data indicate that Nox4 is required for 
TGF-β1-mediated myofibroblasts differentiation and possibly for basal collagen expression and 
moreover expression of α-SMA and fibronectin1. 
In parallel, we utilized Nox4-/--deficient murine dermal fibroblasts in order to prove the 
hypothesis that Nox4 acts as an intracellular mediator of fibroblast activation. If applicable it was 
expected that TGF-β1-mediated expression of collagen type I, α-SMA and fibronectin 1 should 
be abrogated. Indeed, TGF-β1 failed to upregulate gene expression of COL(I)α1, COL(I)α2, α-
SMA, and fibronectin 1 in Nox4-/--deficient cells (Fig. 21B). These findings clearly provide 
strong evidence that endogenous Nox4 represent a crucial intrinsic mediator for TGF-β1-induced 
fibroblast activation as well as differentiation into myofibroblasts. 
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Figure 21. Effect of genetic inhibition of Nox4 on TGF-β1-mediated activation of dermal fibroblasts. 
(A) Nox4 silencing by siRNA suppressed fibroblast activation by TGF-β1. nHDFs were transfected with 
non-targeting siRNA or Nox4 siRNA for 48 hours followed by TGF-β1 treatment for 16 hours and real-
time RT-PCR of Nox4, COL(I)α1, COL(I)α2, α-SMA and fibronectin 1 transcripts was performed. Bars 
represent the means±SEM. n=3; *p<0.05 vs. non-targeting siRNA; #p<0.05 vs. non-targeting 
siRNA+TGF-β1. (B) Nox4 gene ablation abrogated TGF-β1-mediated collagen type I, α-SMA and 
fibronectin 1 expression. Murine Nox4-/- or wild type dermal fibrosarcoma cells were treated with TGF-β1 
for 16 hrs followed by real-time RT-PCR. n=4; *p<0.05 vs. control. #p<0.05 vs. wild type+TGF-β1 
4.5.  Regulation of Nox4 expression by TGF-β1 in HDFs 
4.5.1.  In silico promoter analysis of the human Nox4 gene  
To explore the underlying molecular mechanisms by which TGF-β1 drives Nox4 gene expression 
in HDFs, we employed in silico promoter analysis of the human Nox4 gene. Computer based 
software programs (ALiBaba 2.1/TRANSFAC 8.3) were used to predict potential regulatory 
binding sites for transcription factors within the upstream 4.0 kb region of the human Nox4 
promoter. By this informatic analysis, three putative binding sites were identified: one for 
nuclear factor (erythroid derived 2) like 2 (Nrf2), another for nuclear factor-κB (NF-κB), and a 
third one for Smad3 displaying the highest score (0.99) (Fig. 22). The localization of consensus 
sequences was counted relative to the ATG codon. 
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Figure 22. Mechanisms of TGF-β1-mediated Nox4 expression in nHDFs In silico analysis of 
Nox4 promoter for putative transcription factor binding sites. Each block represents a possible binding 
site: red bars: Smad3; white bars: Nrf2 sites; blue bars: NF-κB sites. The numbers on the axis refer to 
bases upstream from the transcription start site.  
4.5.2.  Nox4 expression is depend on canonical smad3 signaling pathway in HDFs 
To investigate whether RNA stabilization or transcriptional induction mediated the upregulating 
effect of TGF-β1 on Nox4 mRNA expression, nHDFs were pretreated with the mRNA 
polymerase inhibitor actinomycin D for 30 min followed by stimulation with TGF-β1. The 
treatment resulted in a significant decline of Nox4 mRNA level after 16 hrs as shown by real-
time RT-PCR analysis, indicating that TGF-β1-mediated Nox4 mRNA expression occurs via 
transcriptional induction (Fig. 23A).  
It is likely that TGF-β1 activates various intracellular signaling pathways, e. g. canonical and or 
non-canonical pathways (Allison, 2014). To elucidate the mechanism by which the upregulation 
of Nox4 induces dermal fibrosis and also to clarify whether TGF-β1-induced Nox4 expression 
was dependent on canonical Smad signaling pathway, we applied a pharmacological and genetic 
inhibition approach for Smad3. First, preincubation of HDFs with pharmacological specific 
Smad3 inhibitor SIS3 significantly alleviated TGF-β1-induced Nox4 expression (Fig. 23C). To 
further address the involvement of Smad3 in TGF-β1-induced Nox4 expression, siRNA Smad3 
was applied. First, the specificity of siRNA Smad3 (25 nM), mRNA level of Smad3 was 
confirmed by real-time RT PCR analysis. As expected, mRNA level of Smad3 was reduced in 
cells transfected with Smad3 siRNA by ~70 % compared to control siRNA (Fig. 23 B). Second, 
TGF-β1-induced Nox4 up-regulation was partially, however significantly, attenuated by siRNA 
Smad3 in HDFs (Fig. 23D). These data was in accordance with our pervious pharmacological 
data. 
63 | 
Results 
 
Collectively, these data indicate that Smad3 regulates TGF-β1-induced Nox4 upregulation in 
HDFs, providing further evidence that a crosstalk between NADPH oxidases and Smad mediates 
TGF-β1-induced myofibroblasts differentiation. However, we cannot exclude for certain that 
additional transcription factors may be also involved in the upregulation of Nox4 expression in 
response to TGF-β1. 
 
 
Figure 23. Mechanisms of TGF-β1-mediatd Nox4 expression in nHDFs. (A) Nox4 was 
transcriptionally induced by TGF-β1. Prior to stimulation with TGF-β1 (10 ng/ml) for 16 hours nHDFs 
were treated with 5 µg/ml actinomycin D (AD) for 30 min. Nox4 expression was determined by real time 
RT-PCR. n=4; *p<0.01 vs. control; #p<0.01 vs. TGF-β1. (B) Suppression of Smad3 gene expression by 
siRNA in nHDFs. Cells were transfected with Smad3 siRNA (25 nM) or non-targeting siRNA for 48 
hours followed by real-time RT-PCR analysis. n=3; **p<0.01 vs. non-targeting siRNA. (C,D) Impact of 
pharmacological inhibition and gene silencing of Smad3 by siRNA on TGF-β1-mediated Nox4 expression 
in nHDFs. Cells were pretreated with SIS3 (5 µM) for 1 hr followed by stimulation with TGF-β1 
(10  ng/ml) for 16 hrs and real-time RT-PCR. n=3; *p<0.05 vs. control; *p<0.05 vs. TGF-β1. For Smad3 
gene silencing cells were transfected with either non-targeting siRNA or Smad3 siRNA (25 nM) for 48 
hours followed by stimulation with TGF-β1 (10 ng/ml) for 16 hours and real-time RT-PCR analysis. n=3; 
*p<0.05 vs. non-targeting siRNA; #p<0.05 vs. non-targeting siRNA + TGF-β1.   
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4.6.  Pharmacological inhibition of NADPH oxidase activity by DPI reduces 
cutaneous fibrosis in the bleomycin mouse model of scleroderma 
Since both pharmacological inhibition of NADPH oxidase activity by DPI and Nox4-specific 
gene suppression strongly reduced TGF-β1-mediated activation of HDFs, we then utilized the 
bleomycin (BLM) mouse model of scleroderma to verify the effect of this agent in 
experimentally induced skin fibrosis. Mice were administered DPI daily by i. p. injection at a 
dose of 2 mg/kg/day) or vehicle control beginning immediately with BLM injection. None of the 
mice experienced signs of toxicity by the latter treatment. After 30 days of BLM or DPI 
treatment, skin biopsies were harvested from four animal groups followed by RNA extraction, 
assessment dermal thickness, and measurement of collagen content.  
BLM increased the mRNA transcript levels of COL(I)α1 and COL(I)α2 compared to NaCl-
treated animals as shown by real-time RT-PCR analysis (Fig. 24A,B). Treatment with DPI 
markedly reduced or even normalized the cutaneous levels of COL(I)α1 and COL(I)α2 gene 
expression in DPI treated mice compared to NaCl treated mice while it appeared to even slightly 
increase the mRNA levels of collagen type I α2 compared to NaCl-treated mice. Furthermore, 
the effect of Nox inhibition on skin fibrosis in the scleroderma mouse model was also 
determined by analysis of extracellular matrix gene expression (Fig. 24C,D). Interestingly, DPI 
treatment significantly reduced BLM-induced α-SMA and fibronectin I mRNA expression 
compared to mice receiving BLM alone. DPI itself had no effect on the expression of the above 
mentioned genes.  
These mRNA data were confirmed at protein level with regard to cutaneous collagen type I. as 
shown in Fig. 24E. Routine histochemical analysis likewise confirmed the anti-fibrogenic effect 
of DPI compared to animals treated with BLM alone (Fig. 24 F). 
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Figure 24. The NADPH oxidase inhibitor DPI attenuated BLM-induced skin fibrosis.  
(A-D) C3H/HeJ mice were injected daily subcutaneously with BLM (10 µg) alone or in combination with 
daily DPI (i. p., 2 mg/kg). Control mice received NaCl or DPI alone. COL(I)α1, COL(I)α2 were 
determined in skin biopsies after 4 weeks by real-time RT-PCR analysis. n=7 mice per group; *p<0.05. 
(E) Determination of collagen protein content using pepsin digestion methods. Mice were treated as 
above, and proteins were extracted from skin samples, digested with pepsin, and separated by SDS-
PAGE. Results are representative of 6 independent experiments with identical results. (F) Skin fibrosis 
was also assessed by routine histochemistry (H&E staining). Depicted are representative images of each 
treatment group with similar results. Scale bar: 100 µm.  
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4.7.  Nox4 is an emerging novel target for antifibrotic agents 
In a final set of experiments we analyzed the effect of 3 established pharmacological agents on 
TGF-β1-induced Nox4 expression in HDF that have recently been shown to exert fibrosis-
preventing properties in distinct molecular pathways. The peptide α-MSH induces canonical 
cAMP signaling in fibroblasts and prevents bleomycin-induced fibrosis in mice (Böhm, 
Raghunath et al. 2004, Kokot, Sindrilaru et al. 2009). Tropisetron elicits Ca+2 signaling and has 
both antifibrotic and antifibrotic effects (Stegemann, Sindrilaru et al. 2013). Everolimus was 
shown to antagonize TGF-β1-induced collagen secretion and to suppress BLM-induced skin 
fibrosis (Böhm et al, in preparation). Remarkably, treatment with α-MSH suppressed TGF-β1-
mediated Nox4 expression in a dose-dependent manner as shown by real-time RT-PCR 
(Fig.  25A) while neither tropisetron (10 µg/ml) nor everolimus (500 nM) exerted any effects. In 
addition, treatment with α-MSH further attenuated the upregulatory effect of TGF-β1 on α-SMA, 
fibronectin 1, COL(I)α1, and COL(I)α2 gene expression, providing evidence for the first time 
that this peptide might be involved in the regulation of Nox4 gene expression (Fig. 25B-D). 
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Figure 25. α-MSH suppresses TGF-β1-mediated Nox4, Collagen and myofibroblast marker 
genes expression in HDF. Cells were preincubated with α-MSH for 6 hrs as indicated followed 
by stimulation with TGF-β1 (10 ng/ml) for 16 hrs. Expression of Nox4 (A), fibronectin 1 (B), α-
SMA (C), collagen type I α1 and α2 (D) mRNA transcripts was determined by real-time RT-
PCR. n=3; *p<0.05 vs. control; #p<0.01 vs. TGF-β1. 
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5.  Discussion 
SSc is a complex autoimmune disease with an incompletely understood pathogenesis that 
involves autoimmune, vascular and fibrotic damage. Several mediators including TGF-β1 induce 
collagen synthesis and the excessive accumulation of extracellular matrix, making them to 
master regulators of pathological fibrosis. In addition, there is also accumulating evidence that 
abnormal expression and activity of distinct Nox isoforms are involved in the pathogenesis of 
some fibrotic diseases such as lung fibrosis. For example, oxidative stress has been shown to be 
pathogenetically relevant in SSc (Gabrielli, Svegliati et al. 2008, Gabrielli, Svegliati et al. 2012). 
However, the underlying molecular mechanism by which TGF-β1 and oxidative stress-generating 
intracellular enzymes contribute to SSc pathogenesis remains largely unexplored, in particular in 
relevant skin cells such as HDFs. Therefore, the present thesis has been performed to study the 
role of oxidative stress-generating intracellular enzymes in the context of TGF-β1 signaling 
within fibrotic disorders. 
5.1.  Nox4 is abundant in SSc HDFs 
First, we investigated the expression of various Nox isoforms in HDFs from both healthy 
individuals and individuals suffering from SSc. We found that Nox4 mRNA expression was 
relatively abundant in normal HDFs as well as in diseased cells. These findings are in accordance 
with previous studies exploring Nox4 in kidney fibroblasts (Geiszt, Kopp et al. 2000), cardiac 
fibroblasts (Rocic and Lucchesi 2005), lung fibroblasts (Hecker, Vittal et al. 2009), pulmonary 
fibroblasts (Amara, Goven et al. 2010) and renal fibroblasts (Kern, Mair et al. 2014). In contrast 
to previous studies of Sambo (Sambo, Baroni et al. 2001) and (Spadoni, Svegliati Baroni et al. 
2015) we were unable to detect the prototypic Nox isoform Nox2, its cytosolic proteins, or its 
other cytosolic components in normal and SSc HDFs. Similarly, we did not detect transcripts for 
Nox1 in both normal and diseased HDFs. Therefore, further studies are required to clarify these 
discrepancies. Additionally, we could show that healthy HDFs express Nox5, Duox1 and the 
small GTPases Rac1 and Rac2. A very recent study demonstrated that inactivation of Nox4/5 
reduced the indirect harmful effect caused by ROS production and radiation-induced DNA 
damage in human primary fibroblasts, although the interplay between Nox4 and Nox5 enzymatic 
activities in ROS production remained unclear (Weyemi, Redon et al. 2015). Notably, we could 
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not detect Duox1 in our SSc HDFs. To our knowledge the expression of Duox1 has not been 
reported earlier, thus the functional relevance of the previous observation is not clear to date and 
requires further investigations. 
Our data showed differential expression of Nox4 at mRNA and protein levels in both adult HDFs 
and SSc HDF. There was no significant difference at Nox4 mRNA level while Nox4 protein was 
abundant in SSc HDFs. Differential expression was not detected for p22phox and Poldip2. It 
cannot be excluded that larger sample sizes might reveal statistically higher Nox4 expression (at 
the mRNA level) in SSc HDFs than normal HDFs. However, it is well established that changes 
at gene expression levels do not frequently correlate with corresponding changes at protein level. 
In addition, various regulatory mechanisms might occur during gene expression, such as 
transcriptional, post-transcriptional, and translational modification. With respect to these data we 
conclude that gene expression levels do not necessarily reflect protein levels, especially for 
enzymatic proteins (like Nox4) that must undergo post-translational modifications and structural 
or configuration changes at the catalytic core (Maier, Guell et al. 2009, Weake and Workman 
2010). We also speculate that the latter difference might be related to differences in experimental 
culture conditions and/or donor variability. 
Our principal finding that Nox4 protein is highly expressed in SSc HDFs than control cells is 
consistent with recent studies demonstrating an increased in situ immunoreactivity of Nox4 in 
patients with idiopathic lung fibrosis (Hecker, Vittal et al. 2009) and enhanced Nox4 expression 
in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) (Amara, Goven 
et al. 2010). Interestingly, overexpression of Nox4 has been linked to pathological tissue 
remodeling and fibrosis in different organ systems including the heart (Ago, Kuroda et al. 2010, 
Aoyama, Paik et al. 2012), liver (Aoyama, Paik et al. 2012) and kidney (Sedeek, Gutsol et al. 
2013). Furthermore, treatment of HDFs with serum decreased Nox4 expression at the mRNA 
level in a time dependent-manner. Interestingly, the Jiang group showed a negative correlation 
between steady state level of Nox4 mRNA and the serum treatment in endothelial cells 
(Peshavariya, Jiang et al. 2009). Additionally, in pancreatic cancer cells both Nox4 protein 
expression and ROS production were increased after the addition of serum to culture medium. 
The authors proposed that serum could be a powerful inducer of Nox4 protein expression and it 
needs to be considered in future studies concerning Nox4 expression. Thus, the precise role of 
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serum in regulation of Nox4 expression in HDFs is apparently not clear and needs further 
investigations.  
5.2.  Nox4 is colocalized with endoplasmic reticulum in HDFs 
Many studies have shown that Nox4 is localized in different compartments in various cell types 
which influence its functions including enzyme activity, the type of ROS produced and 
downstream signaling mechanisms. Therefore, we investigated the intracellular localization of 
Nox4 in healthy and diseased HDFs. Through laser scanning confocal microscopy, we found that 
Nox4 is localized in the endoplasmic reticulum but not in other cellular compartments such as 
focal adhesions, mitochondria, and lysosomes. In other studies, Nox4 expression was found in 
different organelles. For example, in vascular smooth muscle cells, Nox4 was close to focal 
adhesions (Hilenski, Clempus et al. 2004); in transfected HEK293 cells, it was found in the ER 
(Martyn, Frederick et al. 2006, Chen, Kirber et al. 2008) or in plasma membranes (Lee, Qiao et 
al. 2010). Conversely, in a different study with vascular smooth muscle cells and endothelial 
cells, Nox4 was reported to be localized in the nucleus (Hilenski, Clempus et al. 2004) (Kuroda, 
Nakagawa et al. 2005). Additionally, in somatic cells, Nox4 was detected in mitochondria 
(Block, Gorin et al. 2009).  
Even in the same cell type, different studies have found Nox4 in different locations. This may be 
at least a consequence of Nox4 having yet unknown interaction partners or is due to different 
Nox4 antibodies used in these studies that exhibit various affinities and (cross) reactivates. 
Indeed, Nox4 was demonstrated to relocate from focal adhesions to stress fibers during 
differentiation in vascular smooth muscle cells (Clempus, Sorescu et al. 2007). Based on these 
findings, another hypothesis might be that changes in Nox4 localization correlate with the 
functional or pathological state of cells (Weyemi, Caillou et al. 2010). Here, we found that Nox4 
co-localized with the regulatory protein PDI in the ER in nHFDs and SSc fibroblasts and this 
might suggest that Nox4 is restricted to the ER in nHDFs. 
 Based on our observation, we suggest that a cross talk between NADPH oxidase and ER 
signaling might exist and that PDI might regulate Nox4 activation in HDFs. Notably, Nox4 
activation in response to ER stress has been shown in different studies (Laurindo, Fernandes et 
al. 2008, Santos, Tanaka et al. 2009, Loughlin and Artlett 2010, Amanso, Debbas et al. 2011). In 
addition, it is thought currently that ER stress has a profibrotic role. In a previous study using a 
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rat model of cardiac fibrosis, tunicamycin-induced ER stress along with bleomycin-induced 
fibrosis increased the expression of PDI and cardiac fibrosis  This finding suggests that 
activation of ER stress could affect fibrotic remodeling (Ayala, Montenegro et al. 2012). 
Furthermore, recent evidence revealed a close association between the ER stress and cutaneous 
systemic sclerosis which might have a direct impact in TGF-β1 response in myofibroblast 
activation through induction of ROS production.  
Since Nox4 is the only detectable isoform in HDFs, its activation might link ER stress and 
oxidative stress to the TGF-β1-induced fibroblast activation and eventually development of 
fibrosis. In fact, there are number of recent published papers that link directly or indirectly Nox-
derived ROS to ER stress. According to our findings, Nox4 is up-regulated upon TGF-β1 
stimulation leading to oxidative stress which could trigger the unfolded protein response (UPR) 
signaling that results in ROS production from the ER-resident Nox4 generating a vicious cycle. 
During this process, PDI will activate and promote Nox4 activation to produce hydrogen 
peroxide which subsequently contribute to activation and differentiation of fibroblast into 
myofibroblasts and ultimately lead to fibrosis (Santos, Nabeebaccus et al. 2014), yet, the order 
remains to be determined. Therefore, this organelle might be an important location where Nox4 
produces its main ROS product, hydrogen peroxide. One of the limitation of this study is that we 
did not investigate the effect of the physical interaction between PDI and Nox4, however we 
postulate that Nox4 itself might represent a source of ER -generated ROS and PDI might 
promote the oxidative stress in HDFs by maintaining the Nox4 activity. Thus, PDI might be a 
novel regulator of Nox4 signaling in HDFs contributing to oxidative stress in SSc and further 
studies are required to prove our speculations. Thus, the understanding of such association could 
facilitate further identification the comprehensive mechanism of PDI-Nox activation and its 
potential contribution in fibrotic disorders which remains to be investigated. With better 
understanding of the ROS pathobiology in human cells, it should be possible to develop a 
specific targeted Nox inhibitor or ER-targeted antioxidants which could be used in a combined 
therapy. 
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5.3.  Nox4 expression is regulated by TGF-β1 in HDFs 
In the present study we showed that TGF-β1 strongly induces Nox4 expression, which in turn 
mediates fibroblast activation and synthesis of ECM components. The induction of Nox4 
expression in response to TGF-β1 is consistent with previous findings (Cucoranu, Clempus et al. 
2005, Hecker, Vittal et al. 2009, Bondi, Manickam et al. 2010, Michaeloudes 2011) (Barnes and 
Gorin 2011). However, we were unable to detect a modulatory effect of TGF-β1 upon the 
expression of its associated proteins p22phox and Poldip2. This is in contrast to findings by 
(Manickam, Patel et al. 2014) who demonstrated a role for Poldip2 in TGF-β1-induced Nox4-
dependent ROS production in kidney fibroblasts and subsequent myofibroblast activation. 
Another study also revealed that Nox4 and p22phox were concomitantly increased at the protein 
level in the kidneys of diabetic rats (Etoh, Inoguchi et al. 2003). However, endogenous factors 
such as p22phox and Poldip2 might not need to be upregulated to the same expression level as 
Nox4 to coordinate ROS production. Thus, instead of influencing affect Nox4 expression or 
subcellular localization, these associated proteins might only affect Nox4 stabilization and 
activity (Lyle, Deshpande et al. 2009).  
Although it is well known that TGF-β1 promotes collagen expression and differentiation of 
fibroblasts into myofibroblasts, which are responsible for ECM production leading to fibrotic 
disorders (Takagawa, Lakos et al. 2003, Lakos, Takagawa et al. 2004), little is known about the 
signaling mechanisms that mediate this response. To prove the role of Nox4 in TGF-β1-mediated 
dermal fibrosis, two in vitro approaches were used to inhibit Nox4 activity: a pharmacological 
approach using the NADPH oxidase inhibitor DPI and a genetic approach using specific siRNA 
for Nox4. Overall, inhibiting Nox4 significantly attenuated not only collagen expression but also 
expression of myofibroblasts marker genes such as fibronectin I and α-SMA in response 
to  TGF-β1. For example, when Nox4 was inhibited by DPI, enhanced activity of NADPH 
oxidase was significantly diminished in subcellular fractions. Additionally, in murine Nox4-
deficient dermal fibrosarcoma cells derived from Nox4 knockout mice, TGF-β1 had almost no 
stimulatory effect on collagen synthesis and the expression of myofibroblasts marker genes. 
These findings are in agreement with previous reports demonstrating a similar effect of genetic 
ablation of Nox4 in TGF-β1-mediated induction of collagen and extracellular matrix proteins in 
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lung fibroblasts (Hecker, Vittal et al. 2009), adventitial fibroblasts (Amara, Goven et al. 2010) 
and kidney fibroblasts (Bondi, Manickam et al. 2010). Taken together, we propose that Nox4 
acts as a potent mediator in the downstream profibrotic signaling of TGF-β1 in HDFs, one of the 
main effector cells involved in the development of fibrotic lesions in SSc. 
5.4.  Nox4 expression is regulated by the Smad2/3 pathway in HDFs 
To elucidate the molecular mechanism by which Nox4 modulates TGF-β1-mediated fibroblast 
activation, we investigated the canonical TGF-β1-dependent Smad2/3 pathway. Smad2/3 are 
involved in both the induction of Nox4 and the proliferation of lung fibroblasts (Hecker, Vittal et 
al. 2009), pulmonary vascular smooth muscle cells (Sturrock, Cahill et al. 2006) and endothelial 
cells (Peshavariya, Chan et al. 2014). In addition, there is evidence that several transcription 
factors, such as Smad3, Nrf2, NF-κB and AP1 potentially coordinate in the regulation of Nox 
expression and function (Manea, Manea et al. 2008, Manea, Tanase et al. 2010, Siuda, Zechner 
et al. 2012, Bai, Hock et al. 2014). Therefore, Smad3 was inhibited either pharmacologically by 
SIS3, a smad3 specific inhibitor, or genetically by using specific siRNA for Smad3. Smad 
inhibition led to a partial but significantly reduction in TGF-β1-mediated Nox4 expression. This 
observation is sustained by the findings that TGF-β1 signaling via Smad2/3 was important in the 
transformation of fibroblasts to myofibroblasts and Nox4 was shown to be important in this 
signaling process (Cucoranu, Clempus et al. 2005). That previous study also showed that ROS 
production through Nox4 activation in response to TGF-β1 caused persistent Smad3 activation 
through a feed-forward mechanism. Nonetheless, activation of Nox4 amplifies the H2O2 signal, 
which activates the TGF-β1 signaling pathway through a feedback mechanism (Thannickal 1995, 
Thannickal and Fanburg 1995, Murakami, Ichinohe et al. 2013). Although TGF-β1 was 
originally thought to exert its function through activation of the Smad pathway, recent studies 
have shown that TGF-β1 counteracts other Smad-independent signaling pathways, such as 
MAPK pathways that involve p38, ERK, and JNK. For instance, both TGF-β1-induced canonical 
Smad2 and non-canonical ERK1/2 pathways regulated Nox4 expression in microvascular 
endothelial cells (Jain, Rivera et al. 2013). Although these data provide further evidence that 
Nox4 mediates myofibroblasts activation via TGF-β1/Smad3 signaling, we cannot exclude for 
certain that other pathways might also be involved. 
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5.5.  Nox4 inhibition prevented experimentally induced skin fibrosis in the 
bleomycin mouse model of scleroderma 
To demonstrate the in vivo relevance of our in vitro findings, we used an established mouse 
model of SSc. Herein, dermal fibrosis is induced by daily subcutaneous injections of BLM 
(Yamamoto, Takagawa et al. 1999). We found that pharmacological inhibition of NAPDH 
oxidase activity by DPI prevented experimentally induced skin fibrosis in the BLM mouse model 
of scleroderma. These results are consistent with a previous study by Hecker et al. 2009, who 
showed that Nox4 inhibition (through in vivo DPI administration and in vivo siRNA treatment) 
suppressed BLM-induced lung fibrosis. Further evidence is given by two other in vivo studies 
showing that Nox4 is involved in local TGF-β1-stimulated collagen accumulation (Chan, 
Peshavariya et al. 2013), and BLM administration in p47phox knockout mice lead to markedly 
suppressed collagen deposition in lungs (Manoury, Nenan et al. 2005). Interestingly, a recent 
study demonstrated that Nox4 mRNA and protein expression was increased by BLM and 
reversed by preincubation with roflmilast N-oxide (RNO), the active metabolite of roflmilast 
(Vecchio, Acquaviva et al. 2013). In summary, the in vivo reports together with our in vivo- and 
in vitro findings indicate that anti-fibrotic agents could be beneficial for treating fibrotic 
disorders in humans, in particular for SSc.  
5.6.  α-MSH suppressed TGF-β1-mediated Nox4 gene expression in HDFs 
We finally showed that the peptide α-MSH attenuated TGF-β1-mediated Nox4 induction in a 
dose dependent manner when preincubated before addition of stimulants. Additionally, α-MSH 
could also attenuate the expression of collagen, fibronectin I and α-SMA in response to TGF-β1. 
This result is in agreement with a previous study by (Böhm, Raghunath et al. 2004) who showed 
that α-MSH reduced TGF-β1-mediated collagen synthesis via the melanocortin-1 receptor (MC-
1R in vitro. In vivo, α-MSH was found to attenuate skin fibrosis in the bleomycin scleroderma 
mouse model (Kokot, Sindrilaru et al. 2009). However, in MC-1R-deficient mice, bleomycin-
induced fibrosis is aggravated, suggesting that this receptor has a pathogenic role in fibrotic 
Conditions (Böhm and Stegemann 2014). Phase II trials with a superpotent α-MSH analogue 
have already been conducted for treating a number of skin diseases, including inflammatory 
disorders (Böhm, Ehrchen et al. 2014).  Most recently, a superpotent α-MSH analogue was 
approved for treating the orphan disease erythropoetic protoporphyria (Luger and Böhm 2015). 
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Our finding therefore supports and further extends previous findings in which α-MSH reduced 
BLM-induced intracellular accumulation of ROS in vitro (Kokot, Sindrilaru et al. 2009). It is 
likely that its suppressive effect is mediated by induction of anti-oxidative enzymes and/or 
transcription factors regulating those enzymes.  
Finally, an important perspective would be to determine the mechanism by which α-MSH 
decreases Nox4 gene transcription. α-MSH can upregulate the expression of superoxide 
dismutase 2 and heme oxygenase-1(HO-1) in HDFs. HO-1 expression is under the control of 
Nrf2. It is a crucial transcriptional regulator of antioxidant genes, and it binds to antioxidant 
response elements (AREs), which are present in many cytoprotective genes. Nrf2 is expressed in 
human skin cells such as human dermal fibroblasts, and normal human keratinocytes; moreover, 
in human skin the expression of Nrf2 expression and Nrf-dependent genes is upregulated by α-
MSH. Interestingly, a cross talk between NADPH oxidase and Nrf2 has been suggested in 
endothelial cells. In one study, Nrf2 knockdown by short hairpin RNAs increased Nox4 
expression (Goettsch, Rauner et al. 2011). Kovac recently suggested a negative feedback 
regulatory mechanism between Nox4 and Nrf2 (Kovac, Angelova et al. 2015). Moreover, 
previous studies reported that Nrf2 is decreased in patients with idiopathic pulmonary fibrosis 
(Artaud-Macari, Goven et al. 2013) whereas Nox4 expression is upregulated (Amara, Goven et 
al. 2010). These observations might in part explain the sustained redox imbalance which in turn 
promotes persistent myofibroblasts and fibrosis. Taken together with the above mentioned 
studies, we hypothesized that Nrf2, via upregulation by α-MSH, may antagonize the stimulatory 
effect of TGF-β1 on Nox4 in HDFs.  
Taken together, the findings obtained in this doctoral thesis provide evidence that Nox4 
represents an intracellular nodal point that orchestrates collagen synthesis, differentiation of 
dermal fibroblasts into a profibrotic myofibroblast phenotype, and thus dermal fibrosis as 
summarized in (Fig. 26). These data also indicate that Nox4 could become an important novel 
target for future therapy of SSc and related fibrotic diseases. 
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6.  Conclusion & Future perspectives  
 
The present study provides evidence that targeting Nox4 may represent an effective therapeutic 
strategy for the treatment of fibrotic disorders in SSc patients. We could demonstrate that: 
1) Nox4 is the singular detectable Nox protein in both normal and SSc human dermal fibroblasts 
(HDFs). 
2) TGF-β1 strongly induced Nox4 gene expression in a Smad3-dependent manner. 
3) Genetic silencing of Nox4 abrogated the promoting effect of TGF-β1 on collagen synthesis 
and myofibroblasts differentiation  
4) The non-selective NADPH oxidase inhibitor DPI significantly suppressed skin fibrosis in the 
bleomycin mouse model of scleroderma. 
5) Treatment with α-MSH attenuated TGF-β1-mediated Nox4 expression as well as the 
upregulatory effect of TGF-β1 on α-SMA, fibronectin 1, COL(I)α1, and COL(I)α2 gene 
expression.  
These data strongly indicate that pharmacological targeting of Nox4 may represent a novel 
strategy for the treatment of scleroderma. Therefore, both modulation of Nox4 enzyme activity 
and reduction / suppression of the oxidative stress in patients with SSc with highly Nox4-specific 
inhibitors could have more beneficial effects for SSc patients than the non-selective scavenging 
of ROS by administration of antioxidants. 
Future perspectives 
Recent studies using models of liver and lung fibrosis further sustain the potential therapeutic use 
of a new first-in- small-molecule Nox1/4 inhibitor GKT137831 in the treatment of a broad range 
of fibrotic diseases (Hecker, Logsdon et al. 2014, Lan, Kisseleva et al. 2015, Zhao, 
Viswanadhapalli et al. 2015). GKT137831 is the most recent Nox1/4 inhibitor designed by 
Genkyotex. It displays high oral bioavailability, lacks off-target effects and shows a good safety 
profile in vivo. Currently, it is tested in phase II clinical studies, and very promising results have 
been reported for patients with diabetic kidney disease. In collaboration with Genkyotex, we are 
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therefore interested in investigating whether GKT137831 counteracts fibroblast activation of 
normal and diseased cells alone and in combination with the profibrotic cytokine TGF-β1. 
Interestingly, our preliminary data demonstrate that GKT137831 significantly attenuated TGF-
β1-induced collagen synthesis in nHDFs suggesting that Nox4 specifically contributes to 
myofibroblasts differentiation (Section 7). The next stage would be to explore the potential 
therapeutic effects of GKT137831 in vivo, for example, whether GKT137831 prevents 
bleomycin-induced skin fibrosis and is also capable of reversing an already established fibrosis 
of the skin. One of the major obstacles hindering the development of anti-fibrotic therapies is the 
lack of disease specific biomarkers that can be used to identify local and systemic oxidative 
stress in patients with SSc. Therefore, we intend to analyze the expression of Nox4 as well as 
other suitable biomarkers as biomarkers for a dysregualted ROS production in skin biopsies of 
SSc patients,  
Due to the complexity of Nox4 biology the generation of Nox4-specific antibodies is strongly 
required. Through histological assessment of clinical samples for Nox4 expression utilizing that 
antibodies might allow the identification of abnormalities in specific skin diseases, in particular 
the identification of specific isoform dysfunction. 
Further studies should intend to explore whether PDI has a direct effect on Nox4 activity in 
HDFs and whether knockdown of PDI interferes with Nox4 downstream profibrotic signaling. It 
is also worthwhile to investigate the molecular mechanism by which α-MSH attenuates TGF-β1-
induced Nox4 expression. Further insights into the molecular mechanism by which Nox4 
interacts with partner proteins may facilitate the development of next generation Nox inhibitors. 
Finally, further in vivo studies (e.g. knock down of Nox4 by siRNA in the BLM mouse model or 
use of Nox4-/- mice) are required to definitely validate the benefit of Nox inhibition on skin 
fibrosis as demonstrated in the BLM mouse model of scleroderma and to ensure that Nox4 
definitely control dermal fibrosis. Answers to these questions could move the field of Nox 
biology towards a better understanding of the onset and progression of skin diseases and might 
provide novel targets for therapeutic interventions. 
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7. Pharmacological inhibition of Nox4 by GKT137831 reduces TGF-β1-
mediated fibroblast activation 
 
The role of Nox4 in nHDFs was evaluated using a first-in-class small-molecule of Nox1/4 
inhibitor GKT137831. HDFs were pre-treated with GKT137831 at different doses (0.1-10 µM) 
and then stimulated with TGF-β1 for 16 hrs. Then the expression of established myofibroblasts 
marker genes such as COL(I)α1, COL(I)α2, α-SMA, and fibronectin I was analyzed by real-time 
RT-PCR. Fig. 18A-D shows that the expression of COL(I)α1, 1COL(I) α2, α-SMA and 
fibronectin 1 were increased after stimulation with TGF-β1. Pretreatment of nHDFs with 
GKT137831 significantly attenuated this stimulatory effect of TGF-β1 not only on COL(I)α1 and 
COL(I) α2 gene expression but also expression of α-SMA and fibronectin 1. In contrast, 
GKT137831 per se did not have any significant effect on the basal expression of these genes in 
nHDFs. Notably, GKT137831 when tested at 20-50 µM did not show any significant inhibition 
of TGF-β1-target genes. Taken together, these findings indicate that Nox4 specifically regulates 
activation of HDFs and Nox4-dependent ROS generation are involved in collagen production. 
To confirm these observations at protein level, we are currently investigating the inhibitory effect 
of GKT137831 on TGF-β1-induced collagen type I secretion employing a procollagen type I C-
terminal peptide (PICP) ELISA and will assess the expression of α-SMA and fibronectin 1 by 
immunofluorescence analysis.  
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Figure 27. Effect of pharmacological inhibition of Nox4 via GKT137831 on TGF-β1 mediated 
activation of dermal fibroblasts. (A-D) GKT137831 abrogated TGF-β1-mediated expression of 
COL(I)α1,COL(I) α2, α-SMA and fibronectin I. nHDFs were preincubated with GKT137831 (0.1-10 µM) 
for 1 hour followed by TGF-β1 (10ng/ml) treatment for 16 hrs and real-time RT-PCR. n=3; #p<0.05 vs. 
control; *p<0.01 vs. TGF-β1 and **p<0.05 vs. TGF-β1.  
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Appendix Figure 1. Expression analysis of additional Nox isoforms, adaptor proteins as 
well as Rac1 and Rac2 in normal adult HDFs by endpoint RT-PCR analysis. Expression 
analysis of additional Nox isoforms, adaptor proteins as well as Rac1 and Rac2 in normal nHDFs by 
endpoint RT-PCR analysis. State of the art positive controls consisted of cDNA from HUVEC, normal 
human keratinocytes (NHKs), human peripheral blood monocytes (MNC) and the human colon 
carcinoma cell line CaCo2. Negative controls consisted of HDF templates without RT. Depicted are 
representative images from RT-PCR analyses of n=3 donors. 
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Appendix Figure 2. Confirmation the specificity of Nox4 antibody. (A) nHDFs were 
transfected with non-targeting siRNA or Nox4 siRNA for 48 hours followed by fixation and 
immunofluorescence staining with anti-Nox4 (AlexaFluor488; green). (B) Relative staining intensity was 
evaluated using Image J software. Images are representative for 3 independent experiments with similar 
results. Scale bar: 50 µm. Bars represent the means±SEM. n=3; *p<0.05 vs. non-targeting siRNA. 
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